



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 168212

TO: Tamthom Truong
Location: rem/5B19/5C18
Art Unit: 1624
Tuesday, October 18, 2005
Case Serial Number: 10/088854

From: John DiNatale
Location: Biotech-Chem Library
REM-1B65
Phone: (571)272-2557

john.dinatale@uspto.gov

Search Notes

Examiner Truong,

See attached results.

If you have any questions about this search feel free to contact me at any time.

Thank you for using STIC search services!

John DiNatale
Technical Information Specialist
STIC Biotech/Chem Library
(571)272-2557

This Page Blank (uspto)


[Home](#) [Index](#) [Resources](#) [Contact](#) [Internet Search](#)

168212



Scientific & Technical Information Center



SERVICES

Database Search	submit
PLUS Search	submit
Book/Article Delivery	submit
Book/Journal Purchase	submit
Foreign Patents	submit
Telework Support	
Translation	submit
SIRA Automation Training	
STIC Demos & Events	

RESOURCES

STIC Online Catalog
 Databases
 E-Books [search](#)
 E-Journals [search](#)
 Legal Tools
 Nanotechnology
 Reference Tools

STIC

About Us
 FAQ
 Locations & Hours
 News
 Site Map
 Staff

Search STIC Site

Online Database Search Form

Search requests relating to published applications, patent families, and litigation can be submitted by filling out this form and clicking on "Send."

Tech Center:

☒ TC 1600
 ☐ TC 1700
 ☐ TC 2100
 ☐ TC 2600
 ☐ TC 2800
☐ TC 2900
 ☐ TC 3600
 ☐ TC 3700
 ☐ Law Lib
 ☐ Other

Your Contact Information:

* indicates mandatory information.

Your Name:

*Email Address:
 (e.g., Susan.Smith@uspto.gov)

*Employee No.:

*Art Unit/Org.:

*Office Location:

*Phone No.:

Mailbox No.:

RECEIVED
 OCT 11 2000
 TECH/CHIEF, E.O.
 (STIC)

*Case serial number:

If not related to a patent application, please enter NA here.

Class / Subclass(es)

Earliest Priority Filing Date:

Format preferred for results:

☒ Paper
 ☐ Diskette
 ☐ E-mail


Provide detailed information on your search topic:

- In your own words, describe in detail the concepts or subjects you want us to search.
- Include synonyms, keywords, and acronyms. Define terms that have special meaning.
- *For Chemical Structure Searches Only*
 Include the elected species or structures, keywords, synonyms, acronyms, and chemical structure.
- *For Sequence Searches Only*
 Include all pertinent information (parent, child, divisional, or issued patent number and serial number).
- *For Foreign Patent Family Searches Only*
 Include the country name and patent number.

This Page Blank (uspto)

10/088,854

Query



$X = O, S, S(O), S(O)_2, NH \text{ or } NR^8$

$R^8 = H \text{ or alkyl}$

$Z = O \text{ or } S$

$R^9 = H, \text{ ethenyl, opt. sub. phenyl,}$
 $\text{opt. sub. pyridyl, or opt. sub. furanyl.}$

See also claim 11

This Page Blank (uspto)



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov



Bib Data Sheet

CONFIRMATION NO. 6749

SERIAL NUMBER 10/088,854	FILING DATE 03/21/2002 RULE	CLASS 514	GROUP ART UNIT 1624	ATTORNEY DOCKET NO. Z70601-1
-----------------------------	---------------------------------------	--------------	------------------------	------------------------------------

APPLICANTS

Andrew Austen Mortlock, Macclesfield, UNITED KINGDOM;
 Nicholas John Keen, Macclesfield, UNITED KINGDOM;

It audit

**** CONTINUING DATA *******
 This application is a 371 of PCT/GB00/03556 09/18/2000

**** FOREIGN APPLICATIONS *******
 UNITED KINGDOM 9922156.6 09/21/1999
 UNITED KINGDOM 9922152.5 09/21/1999
 UNITED KINGDOM 9922159.0 09/21/1999

Foreign Priority claimed 35 USC 119 (a-d) conditions met Verified and Acknowledged	<input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> Met after Allowance Examiner's Signature _____ Initials _____	STATE OR COUNTRY UNITED KINGDOM	SHEETS DRAWING	TOTAL CLAIMS 15	INDEPENDENT CLAIMS 1
--	--	--	-----------------------	-----------------------	----------------------------

ADDRESS
 44992
 ASTRAZENECA R&D BOSTON
 35 GATEHOUSE DRIVE
 WALTHAM, MA
 02451-1215

TITLE
 Quinazoline compounds and pharmaceutical compositions containing them

FILING FEE	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT	<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees (Filing) <input type="checkbox"/> 1.17 Fees (Processing Ext. of time)
------------	---	--

This Page Blank (uspto)

RECEIVED 1170	No. _____ for following:	<table border="1"><tr><td><input type="checkbox"/> 1.18 Fees (Issue)</td></tr><tr><td><input type="checkbox"/> Other _____</td></tr><tr><td><input type="checkbox"/> Credit</td></tr></table>	<input type="checkbox"/> 1.18 Fees (Issue)	<input type="checkbox"/> Other _____	<input type="checkbox"/> Credit
<input type="checkbox"/> 1.18 Fees (Issue)					
<input type="checkbox"/> Other _____					
<input type="checkbox"/> Credit					

This Page Blank (uspto)

Application No. 10/088,354
 Amendment Dated 08/12/2005
 Reply to Office Action of 03/14/2005


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-10. (Cancelled)

11. (Currently amended) A compound of formula (IIB)



(IIB)

or a salt, ester, amide or prodrug thereof

where

X is O, or S, S(O) or S(O)₂, NH or NR⁹ where R⁹ is hydrogen or C₁₋₆alkyl,

Z is O or S,

R⁹ is hydrogen or optionally substituted hydrocarbyl or optionally substituted heterocyclyl ethenyl, optionally substituted phenyl, optionally substituted pyridyl or optionally substituted furanyl where optional substituents for R⁹ groups are C₁₋₃alkoxy, C₁₋₃alkyl, halo or nitro,

R⁶ and R⁷ are independently selected from hydrogen, halo, C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄alkoxymethyl, di(C₁₋₄alkoxy)methyl, C₁₋₄alkanoyl, trifluoromethyl, cyano, amino, C₂₋₆alkenyl, C₂₋₆alkynyl, a phenyl group, a benzyl group or a 5-6-membered heterocyclic group with 1-3 heteroatoms, selected independently from O, S and N, which heterocyclic group may be aromatic or non-aromatic and may be saturated and [(I)]linked via a ring carbon or nitrogen atom[(D)] or unsaturated and [(I)]linked via a ring carbon atom[(D)], and which phenyl, benzyl or heterocyclic group may bear on one or more ring carbon atoms up to 5 substituents selected from hydroxy, halogeno, C₁₋₃alkyl, C₁₋₃alkoxy, C₁₋₃alkanoyloxy, trifluoromethyl, cyano, amino, nitro, C₂₋₄alkanoyl, C₁₋₄alkanoylamino, C₁₋₄alkoxycarbonyl, C₁₋₄alkylsulphanyl, C₁₋₄alkylsulphinyl, C₁₋₄alkylsulphonyl, carbamoyl, N-C₁₋₄alkylcarbamoyl, N,N-di(C₁₋₄alkyl)carbamoyl,

This Page Blank (uspto)

Application No. 10/088,354
 Amendment Dated 08/12/2005
 Reply to Office Action of 03/14/2005

aminosulphonyl, N-C₁₋₄alkylaminosulphonyl, N,N-di(C₁₋₄alkyl)aminosulphonyl, C₁₋₄alkylsulphonylamino, and a saturated heterocyclic group selected from morpholino, thiomorpholino, pyrrolidinyl, piperazinyl, piperidinyl, imidazolidinyl and pyrazolidinyl, which saturated heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, C₁₋₃alkyl, C₁₋₃alkoxy, C₁₋₃alkoxyloxy, trifluoromethyl, cyano, amino, nitro and C₁₋₄alkoxycarbonyl, R¹ is hydrogen, R⁴ is hydrogen, halo, C₁₋₄alkyl or C₁₋₄alkoxy are independently selected from halogeno, cyano, nitro, C₁₋₃alkylsulphonyl, N(OH)R¹² (wherein R¹² is hydrogen, or C₁₋₃alkyl), or R¹⁴X¹ (wherein X¹ represents a direct bond, -O-, -CH₂-, -OC(O)-, -C(O)-, -S-, -SO-, -SO₂-, -NR¹⁵C(O)-, -C(O)NR¹⁶-, -SO₂NR¹⁷-, -NR¹⁸SO₂- or -NR¹⁹- (wherein R¹⁵, R¹⁶, R¹⁷, R¹⁸ and R¹⁹ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl)), and R¹⁴ is hydrogen, optionally substituted hydrocarbyl, optionally substituted heterocyclyl or optionally substituted alkoxy

and n is 0, or an integer of from 1 to 6,


R²⁰ is halo, cyano, nitro, trifluoromethyl, C₁₋₃alkyl, -NR¹²R¹³ [(I) wherein R¹² and R¹³, which may be the same or different, each represents hydrogen or C₁₋₃alkyl(I)], or a group -X¹R¹⁴ [(I) wherein X¹ represents a direct bond, -O-, -CH₂-, -OC(O)-, -C(O)-, -S-, -SO-, -SO₂-, -NR¹⁵C(O)-, -C(O)NR¹⁶-, -SO₂NR¹⁷-, -NR¹⁸SO₂- or -NR¹⁹- [(I) wherein R¹⁵, R¹⁶, R¹⁷, R¹⁸ and R¹⁹ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl(I)]], and R¹⁴ is hydrogen or C₁₋₃alkyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, oxiranyl, fluoro, chloro, bromo and amino including C₁₋₃alkyl and trifluoromethyl; or -R³⁰R³⁰ and wherein R³⁰ represents a pyridone group, a phenyl group or a 5-6-membered aromatic heterocyclic group linked via carbon or nitrogen with 1-3 heteroatoms selected from O, N and S, which pyridone, phenyl or aromatic heterocyclic group may carry up to 5 substituents selected from hydroxy, nitro, halogeno, amino, C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄hydroxyalkyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, C₁₋₄hydroxyalkoxy, oxo, cyano, C₁₋₄alkyl, cyclopropyl, C₁₋₄alkylsulphonyl, C₁₋₄alkyl, C₁₋₄alkoxycarbonyl, di(C₁₋₄alkyl)amino, C₁₋₄alkylaminoC₁₋₄alkyl, C₁₋₄alkanoyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkoxy, di(C₁₋₄alkyl)aminoC₁₋₄alkoxy, carboxy, carboxamido, trifluoromethyl, cyano, -C(O)NR³⁹R⁴⁰, -NR⁴¹C(O)R⁴² wherein R³⁹, R⁴⁰, R⁴¹ and R⁴², which may be the same or different, each represents hydrogen, C₁₋₄alkyl, hydroxyC₁₋₄alkyl or C₁₋₃alkoxyC₂₋₃alkyl and a group -(O)_f(C₁₋₄alkyl)_g ring D wherein f is 0 or 1, g is 0 or 1 and ring D is a cyclic group selected from C₃₋₆cycloalkyl, aryl or 5-6 membered saturated or unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from halo and C₁₋₄alkyl; and wherein R⁹ is a C₁₋₃alkylene group optionally

This Page Blank (uspto)

Application No. 10/088,354
 Amendment Dated 08/12/2005
 Reply to Office Action of 03/14/2005

substituted by one or more substituents selected from hydroxy, halogeno and amino hydrogen, optionally substituted hydrocarbyl, optionally substituted heterocyclyl or optionally substituted alkoxy;

and R^{57} is C_{1-3} alkoxy optionally substituted with a group X^1R^{38} [(I)] wherein X^1 represents a direct bond, O , CH_2 , $OC(O)$, $C(O)$, S , SO , SO_2 , $NR^{15}C(O)$, $C(O)NR^{16}$, SO_2NR^{17} , $NR^{18}SO_2$ or NR^{19} (wherein R^{15} , R^{16} , R^{17} , R^{18} and R^{19} each independently represents hydrogen, C_{1-3} alkyl or C_{1-3} alkoxy C_{2-3} alkyl); and R^{38} are as defined above is a pyridone-group, an aryl-group or an aromatic heterocyclic group (linked via carbon or nitrogen) with 1-3 heteroatoms selected from O, N and S, which pyridone, aryl or aromatic heterocyclic group may be substituted by one or more functional groups or by a hydrocarbyl group optionally substituted by one or more functional groups or heterocyclyl groups, or by a heterocyclyl group optionally substituted by one or more functional groups or hydrocarbyl groups, or R^{57} is 3-morpholinopropoxy; provided that R^{57} is other than unsubstituted alkoxy; or a compound of formula (IIIb)



(IIIb)

or a salt, ester, amide or prodrug thereof,


where X , R^1 , R^4 , R^5 and R^7 are as defined above, and R^{60} and R^{57} are as defined above provided that R^{57} is other than unsubstituted alkoxy; and R^6 is benzyl or cyanobenzyl or R^6 is optionally substituted phenyl, where the optional substituents include C_{1-3} alkyl groups as well as nitro and halo or R^6 is ethynyl optionally substituted with trimethylsilyl groups, carboxy, or an C_{1-3} alkyl ester thereof;

or

a compound of formula (IVb)

is Page Blank (uspto)

Application No. 10/088,354
 Amendment Dated 08/12/2005
 Reply to Office Action of 03/14/2005




(IVB)

or a salt, ester, amide or prodrug thereof,

where X, R¹, R², R³ and R⁴ are as defined above, R⁵ is a group of formula NR¹⁰R^{10'} where R¹⁰ and R^{10'} are independently selected from hydrogen, optionally substituted hydrocarbyl or optionally substituted heterocyclyl, or R¹⁰ and R^{10'} together with the nitrogen atom to which they are attached form an optionally substituted heterocyclic ring which may optionally contain further heteroatoms, or an azo group of formula -N=N-R¹¹ where R¹¹ is an optionally substituted hydrocarbyl group or optionally substituted heterocyclyl group, or R⁵ is a group -N=NR¹¹ where R¹¹ is as defined above, and R⁶ and R⁷ are as defined above provided that R⁶ is other than unsubstituted alkoxy;

or

a compound of formula (IVC)



(IVC)

or a salt, ester, amide or prodrug thereof,

where R¹, R², R³, R⁴ and X are as defined in claim 1.



STIC SEARCH RESULTS FEEDBACK FORM

Biotech-Chem Library

Questions about the scope or the results of the search? Contact ***the searcher or contact:***

Mary Hale, Information Branch Supervisor
Remsen Bldg. 01 D86
571-272-2507

Voluntary Results Feedback Form

➤ I am an examiner in Workgroup: Example: 1610

➤ Relevant prior art **found**, search results used as follows:

- ☐ 102 rejection
- ☐ 103 rejection
- ☐ Cited as being of interest.
- ☐ Helped examiner better understand the invention.
- ☐ Helped examiner better understand the state of the art in their technology.

Types of relevant prior art found:

- ☐ Foreign Patent(s)
- ☐ Non-Patent Literature
(journal articles, conference proceedings, new product announcements etc.)

➤ Relevant prior art **not found**:



- ☐ Results verified the lack of relevant prior art (helped determine patentability).
- ☐ Results were not useful in determining patentability or understanding the invention.

Comments:

Drop off or send completed forms to STIC-Biotech-Chem Library Remsen Bldg.



Page Blank (uspto)



chain nodes :

11 12 13 14 15 16 17 24 26 27 29 31 32 35 36 40

ring nodes :

1 2 3 4 5 6 7 8 9 10

ring/chain nodes :

28 30

chain bonds :

7-11 11-24 14-15 16-17 24-40 26-28 27-30 28-29 30-31 30-32

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10

exact/norm bonds :

5-7 6-10 7-8 7-11 8-9 9-10 11-24 14-15 16-17 24-40 26-28 27-30 28-29 30-31
30-32

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

G1: [*1], [*2], [*3], [*4]

G2: [*5], [*6], [*7], [*8]

Connectivity :

8:2 E exact RC ring/chain 10:2 E exact RC ring/chain 29:1 E exact RC ring/chain

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:CLASS
12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 24:Atom 26:CLASS 27:CLASS
28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS 35:CLASS 36:CLASS 40:CLASS

Generic attributes :

This Page Blank (uspto)


24:

Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic

Element Count :

Node 24: Limited
C,C6

This Page Blank (uspic)



chain nodes :

11 12 13 18 20 21 22 23 24 25 26 27 28 29 30 31 33 34 35 36 37 38
39 40 48 49 61 62 63 64 73 74 75 76 77 78 83 84 90 92 93 95 96 98

ring nodes :

1 2 3 4 5 6 7 8 9 10 42 43 44 45 46 47

chain bonds :

7-90 18-90 18-98 20-92 21-93 22-61 23-63 24-25 26-27 27-28 29-30 30-31 33-34
35-36 36-37 38-39 39-40 61-62 62-95 63-64 64-96 73-75 74-76 75-77 76-78

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 42-43 42-47 43-44 44-45
45-46 46-47

exact/norm bonds :

5-7 6-10 7-8 7-90 8-9 9-10 18-90 18-98 20-92 21-93 24-25 26-27 27-28 29-30
30-31 33-34 35-36 36-37 38-39 39-40 62-95 64-96

exact bonds :

22-61 23-63 61-62 63-64 73-75 74-76 75-77 76-78

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 42-43 42-47 43-44 44-45 45-46 46-47

G1: [*1], [*2], [*3]

G2: [*4], [*5], [*6], [*7], [*8], [*9], [*10], [*11], [*12]

G3: [*13], [*14], [*15], [*16], [*17], [*18], [*19], [*20]

Connectivity :

This Page Blank (uspto)

8:2 E exact RC ring/chain 10:2 E exact RC ring/chain 24:2 E exact RC ring/chain
 25:1 E exact RC ring/chain 26:2 E exact RC ring/chain 27:2 E exact RC ring/chain
 28:1 E exact RC ring/chain 29:2 E exact RC ring/chain 30:2 E exact RC ring/chain
 31:1 E exact RC ring/chain 33:2 E exact RC ring/chain 34:1 E exact RC ring/chain
 35:2 E exact RC ring/chain 36:2 E exact RC ring/chain 37:1 E exact RC ring/chain
 38:2 E exact RC ring/chain 39:2 E exact RC ring/chain 40:1 E exact RC ring/chain

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:CLASS
 12:CLASS 13:CLASS 18:Atom 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS
 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS 33:CLASS 34:CLASS 35:CLASS
 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS 42:Atom 43:Atom 44:Atom 45:Atom
 46:Atom 47:Atom 48:Atom 49:Atom 61:CLASS 62:CLASS 63:CLASS 64:CLASS 73:CLASS
 74:CLASS 75:CLASS 76:CLASS 77:CLASS 78:CLASS 83:CLASS 84:CLASS 90:CLASS 92:CLASS
 93:CLASS 95:CLASS 96:CLASS 98:CLASS

Generic attributes :

18:
 Saturation : Unsaturated
 Number of Carbon Atoms : less than 7
 Type of Ring System : Monocyclic
 48:
 Saturation : Unsaturated
 Number of Carbon Atoms : less than 7
 Number of Hetero Atoms : less than 2
 Type of Ring System : Monocyclic
 49:
 Saturation : Unsaturated
 Number of Carbon Atoms : less than 7
 Number of Hetero Atoms : less than 2
 Type of Ring System : Monocyclic


Element Count :

Node 18: Limited
 C,C6

Node 48: Limited
 C,C5
 N,N1

Node 49: Limited
 C,C4
 O,O1

This Page Blank (uspto)



chain nodes :

12 13 15 20 22 23 24 31 33 34 36 37 38 39 40 41 42 46 47 48 49 50
51 52 53 54 55 56 57 59 60 62 63 64 65 66 67 69 70 83

ring nodes :

1 2 3 4 5 6 7 8 9 10 25 26 27 28 29 30

chain bonds :

1-20 2-23 7-22 13-15 23-24 24-83 31-33 36-59 37-60 38-39 38-40 38-62 41-42
41-63 46-64 47-48 48-49 48-65 50-51 50-52 52-66 53-54 54-67 55-56 56-69 57-70

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 25-26 25-30 26-27 27-28
28-29 29-30

exact/norm bonds :

1-20 2-23 5-7 6-10 7-8 7-22 8-9 9-10 13-15 23-24 24-83 31-33 36-59 37-60
38-39 38-40 38-62 41-42 41-63 46-64 47-48 48-49 48-65 50-51 50-52 52-66 53-54
54-67 55-56 56-69 57-70

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 25-26 25-30 26-27 27-28 28-29 29-30

G1:H,X, [*1], [*2]

G2:O,S,N

G3: [*3], [*4], [*5]

G4: [*3], [*4], [*5], [*6], [*7], [*8], [*9], [*10], [*11], [*12], [*13], [*14], [*15]

Connectivity :

This Page Blank (uspto)

4:2 E exact RC ring/chain 8:2 E exact RC ring/chain 10:2 E exact RC ring/chain
12:2 X maximum RC ring/chain 13:2 X maximum RC ring/chain 33:1 E exact RC ring/chain

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 12:CLASS
13:CLASS 15:CLASS 20:CLASS 22:CLASS 23:CLASS 24:CLASS 25:Atom 26:Atom 27:Atom
28:Atom 29:Atom 30:Atom 31:Atom 33:CLASS 34:Atom 36:CLASS 37:CLASS 38:CLASS
39:CLASS 40:CLASS 41:CLASS 42:CLASS 46:CLASS 47:CLASS 48:CLASS 49:CLASS 50:CLASS
51:CLASS 52:CLASS 53:CLASS 54:CLASS 55:CLASS 56:CLASS 57:CLASS 59:CLASS 60:CLASS
62:CLASS 63:CLASS 64:CLASS 65:CLASS 66:CLASS 67:CLASS 69:CLASS 70:CLASS 83:CLASS

Generic attributes :

31:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : less than 2
Type of Ring System : Monocyclic
34:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic

Element Count :

Node 12: Limited
C,C1-4

Node 13: Limited
C,C1-4

Node 24: Limited
C,C1-8

Node 31: Limited
C,C5
N,N1

Node 34: Limited
C,C2-5
O,O0-3
N,N0-3
S,S0-3

This Page Blank (uspto)

Structure Search in Registry

Truong 10_088854

(crossover to

CAPLUS, USPatFull,

10/18/2005

USPat2, Toxcenter)

=> file registry

FILE 'REGISTRY' ENTERED AT 14:45:34 ON 18 OCT 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 17 OCT 2005 HIGHEST RN 865410-76-0

DICTIONARY FILE UPDATES: 17 OCT 2005 HIGHEST RN 865410-76-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005. A new display format, IDERL, is now     *
* available and contains the CA role and document type information. *
*
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> file caplus

FILE 'CAPLUS' ENTERED AT 14:45:37 ON 18 OCT 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Oct 2005 VOL 143 ISS 17

FILE LAST UPDATED: 17 Oct 2005 (20051017/ED)


Effective October 17, 2005, revised CAS Information Use Policies apply.

<http://www.cas.org/infopolicy.html>

=> d stat que L15

The diagram shows a chemical structure with the following components and labels:

- Central Ring:** A six-membered ring with vertices labeled 1 through 10. Vertices 1, 2, 3, and 4 are connected by dashed lines, while vertices 5, 6, 7, 8, 9, and 10 are connected by solid lines. The ring contains two nitrogen atoms (N) at positions 8 and 10, and four carbon atoms (C) at positions 1, 2, 3, and 4.
- Left Side:** A group labeled "16 Ak" is connected to a nitrogen atom labeled "N 15".
- Top Left:** An oxygen atom labeled "O 12" and a sulfur atom labeled "S 13" are shown.
- Top Center:** A group labeled "14 NM1" is shown.
- Right Side:** A long chain of zig-zag lines connects the central ring (specifically vertex 7) to a group labeled "G1". This chain passes through a vertex labeled "11" and ends at a vertex labeled "17 Cb". Further along the chain is a vertex labeled "G2", which is connected to a final vertex labeled "27".
- Bottom Right:** An oxygen atom labeled "O 25" and a sulfur atom labeled "S 26" are shown.



VAR G1=12-7 12-17/13-7 13-17/14-7 14-17/15-7 15-17

NODE ATTRIBUTES:

HCOUNT IS M1 AT 14
HCOUNT IS M1 AT 18
HCOUNT IS M1 AT 19
NSPEC IS R AT 1
NSPEC IS R AT 2
NSPEC IS R AT 3
NSPEC IS R AT 4
NSPEC IS R AT 5
NSPEC IS R AT 6
NSPEC IS R AT 7
NSPEC IS R AT 8
NSPEC IS R AT 9
NSPEC IS R AT 10
NSPEC IS C AT 11
NSPEC IS C AT 12
NSPEC IS C AT 13
NSPEC IS C AT 14
NSPEC IS C AT 15
NSPEC IS C AT 16
NSPEC IS C AT 17
NSPEC IS C AT 18
NSPEC IS C AT 19
NSPEC IS RC AT 20
NSPEC IS C AT 21
NSPEC IS RC AT 22
NSPEC IS C AT 23
NSPEC IS C AT 24
NSPEC IS C AT 25
NSPEC IS C AT 26
NSPEC IS C AT 27
CONNECT IS E2 RC AT 8
CONNECT IS E2 RC AT 10
CONNECT IS E1 RC AT 21
DEFAULT MLEVEL IS ATOM
MLEVEL IS CLASS AT 12 13 14 15 16 18 19 20 21 22 23 24 25 26
GGCAT IS MCY LOC UNS AT 17
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS E6 C AT 17

GRAPH ATTRIBUTES:





RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 27

STEREO ATTRIBUTES: NONE

L2 5754 SEA FILE=REGISTRY SSS FUL L1
L5 STR

Hy 42




Hy 41



O 11


S 12

N 13



Page 1-A

20








28


0

∴


Page 1-B




Page 2-A



Page 2-B



Page 3-A



Page 3-B

VAR G1=11-7 11-14/12-7 12-14/13-7 13-14
 VAR G2=19/21/24/27/29/32/35/41/42
 VAR G3=15/16/17/18/49/50/57/58
 REP G17=(0-6) 52-50 52-54
 REP G18=(0-6) 51-49 51-53
 REP G19=(0-6) 45-18 45-46
 REP G20=(0-6) 43-17 43-44
 NODE ATTRIBUTES:
 HCOUNT IS M2 AT 43
 HCOUNT IS M2 AT 44
 HCOUNT IS M2 AT 45
 HCOUNT IS M2 AT 46
 HCOUNT IS M2 AT 51
 HCOUNT IS M2 AT 52
 HCOUNT IS M3 AT 53
 HCOUNT IS M3 AT 54

HCOUNT	IS M1	AT	57
HCOUNT	IS M1	AT	58
NSPEC	IS R	AT	1
NSPEC	IS R	AT	2
NSPEC	IS R	AT	3
NSPEC	IS R	AT	4
NSPEC	IS R	AT	5
NSPEC	IS R	AT	6
NSPEC	IS R	AT	7
NSPEC	IS R	AT	8
NSPEC	IS R	AT	9
NSPEC	IS R	AT	10
NSPEC	IS C	AT	11
NSPEC	IS C	AT	12
NSPEC	IS C	AT	13
NSPEC	IS C	AT	14
NSPEC	IS C	AT	15
NSPEC	IS C	AT	16
NSPEC	IS C	AT	17
NSPEC	IS C	AT	18
NSPEC	IS C	AT	19
NSPEC	IS C	AT	20
NSPEC	IS C	AT	21
NSPEC	IS C	AT	22
NSPEC	IS C	AT	23
NSPEC	IS C	AT	24
NSPEC	IS C	AT	25
NSPEC	IS C	AT	26
NSPEC	IS C	AT	27
NSPEC	IS C	AT	28
NSPEC	IS C	AT	29
NSPEC	IS C	AT	30
NSPEC	IS C	AT	31
NSPEC	IS C	AT	32
NSPEC	IS C	AT	33
NSPEC	IS C	AT	34
NSPEC	IS R	AT	35
NSPEC	IS R	AT	36
NSPEC	IS R	AT	37
NSPEC	IS R	AT	38
NSPEC	IS R	AT	39
NSPEC	IS R	AT	40
NSPEC	IS C	AT	41
NSPEC	IS C	AT	42
NSPEC	IS C	AT	43
NSPEC	IS C	AT	44
NSPEC	IS C	AT	45
NSPEC	IS C	AT	46
NSPEC	IS C	AT	47
NSPEC	IS C	AT	48
NSPEC	IS C	AT	49
NSPEC	IS C	AT	50
NSPEC	IS C	AT	51
NSPEC	IS C	AT	52
NSPEC	IS C	AT	53
NSPEC	IS C	AT	54
NSPEC	IS C	AT	55
NSPEC	IS C	AT	56
NSPEC	IS C	AT	57

```

NSPEC   IS C      AT  58
NSPEC   IS C      AT  59
NSPEC   IS C      AT  60
NSPEC   IS C      AT  61
NSPEC   IS C      AT  62
NSPEC   IS C      AT  63
NSPEC   IS C      AT  64
CONNECT IS E2    RC AT   8
CONNECT IS E2    RC AT  10
CONNECT IS E2    RC AT  19
CONNECT IS E1    RC AT  20
CONNECT IS E2    RC AT  21
CONNECT IS E2    RC AT  22
CONNECT IS E1    RC AT  23
CONNECT IS E2    RC AT  24
CONNECT IS E2    RC AT  25
CONNECT IS E1    RC AT  26
CONNECT IS E2    RC AT  27
CONNECT IS E1    RC AT  28
CONNECT IS E2    RC AT  29
CONNECT IS E2    RC AT  30
CONNECT IS E1    RC AT  31
CONNECT IS E2    RC AT  32
CONNECT IS E2    RC AT  33
CONNECT IS E1    RC AT  34
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS AT  11 12 13 15 16 17 18 19 20 21 22 23 24 25 26 27 28
        29 30 31 32 33 34 43 44 45 46 49 50 51 52 53 54 57 58
GGCAT   IS MCY   LOC  UNS  AT  14
GGCAT   IS MCY   LOC  LOQ  UNS  AT  41
GGCAT   IS MCY   LOC  LOQ  UNS  AT  42
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS E6 C   AT  14
ECOUNT  IS E5 C   E1 N   AT  41
ECOUNT  IS E4 C   E1 O   AT  42

```

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 64

STEREO ATTRIBUTES: NONE

L8 3987 SEA FILE=REGISTRY SUB=L2 SSS FUL L5
L9 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

L14 89 SEA FILE=REGISTRY SUB=L8 SSS FUL L9
L15 8 SEA FILE=CAPLUS ABB=ON PLU=ON L14

=> file uspatall toxcenter

FILE 'USPATFULL' ENTERED AT 14:48:22 ON 18 OCT 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 14:48:22 ON 18 OCT 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'TOXCENTER' ENTERED AT 14:48:22 ON 18 OCT 2005

COPYRIGHT (C) 2005 ACS

=> d stat que nos L23

L1 STR
L2 5754 SEA FILE=REGISTRY SSS FUL L1
L5 STR
L8 3987 SEA FILE=REGISTRY SUB=L2 SSS FUL L5
L9 STR
L14 89 SEA FILE=REGISTRY SUB=L8 SSS FUL L9
L23 14 SEA L14

=> dup rem L15 L23

FILE 'CAPLUS' ENTERED AT 14:50:13 ON 18 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 14:50:13 ON 18 OCT 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 14:50:13 ON 18 OCT 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)


FILE 'TOXCENTER' ENTERED AT 14:50:13 ON 18 OCT 2005
COPYRIGHT (C) 2005 ACS
PROCESSING COMPLETED FOR L15
PROCESSING COMPLETED FOR L23
L24 15 DUP REM L15 L23 (7 DUPLICATES REMOVED)
ANSWERS '1-8' FROM FILE CAPLUS
ANSWERS '9-15' FROM FILE USPATFULL

=> d ibib abs hitstr L24 1-15

L24 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 1
ACCESSION NUMBER: 2002:888722 CAPLUS
DOCUMENT NUMBER: 137:384857
TITLE: Preparation of 4-anilinoquinazolines as antitumor agents
INVENTOR(S): Hennequin, Laurent Francois Andre; Ple, Patrick
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2002092579	A1	20021121	WO 2002-GB2128	20020508
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,			

CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 PRIORITY APPLN. INFO.: EP 2001-401221 A 20010514
 OTHER SOURCE(S): MARPAT 137:384857
 GI




AB The title compds. [I; R1 = H, OH, alkoxy and R2 = hydroxyalkoxy, alkoxyalkoxy, aminoalkoxy, etc.; or R2 = H, OH, alkoxy and R1 = hydroxyalkoxy, alkoxyalkoxy, aminoalkoxy, etc.; R3 = Cl, Br, I], useful as an anti-invasive agents in the containment and/or treatment of solid tumor disease, were prepared and formulated. E.g., a multi-step synthesis of I.2HCl [R1 = OMe; R2 = 3-(4-methylpiperazin-1-yl)propoxy; R3 = Cl], starting from 2-amino-4-benzyloxy-5-methoxybenzamide, was given. The biol. activity of compds. I was tested in 4 tests. Thus, the compds. I showed IC50 of 0.001-10 μ M in in vitro c-Src tyrosine kinase assay.

IT **476156-86-2P**, 7-Benzyloxy-4-(2-chloro-5-methoxyanilino)-6-methoxyquinazoline
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of 4-anilinoquinazolines as antitumor agents)

RN 476156-86-2 CAPLUS

CN 4-Quinazolinamine, N-(2-chloro-5-methoxyphenyl)-6-methoxy-7-(phenylmethoxy) - (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 2002:888720 CAPLUS


DOCUMENT NUMBER: 137:384855

TITLE: Preparation of 4-anilinoquinazolines as antitumor

agents
 INVENTOR(S): Hennequin, Laurent Francois Andre; Ple, Patrick
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
 SOURCE: PCT Int. Appl., 96 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002092577	A1	20021121	WO 2002-GB2117	20020508
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: EP 2001-401223 A 20010514
 OTHER SOURCE(S): MARPAT 137:384855
 GI




I

AB The title compds. [I; R1 = H, alkoxy and R2 = X1Q1 (wherein X1 = O, S, SO, etc.; Q1 = heteroaryl, heteroarylalkyl, heterocyclyl, etc.), X2R5 (wherein X2 = O, NH, Nalkyl; R5 = hydroxyalkyl, alkoxyalkyl, aminoalkyl, etc.); or R2 = H, alkoxy and R1 = X1Q1, X2R5; R3 = Cl, Br, I], useful as anti-invasive agents in the containment and/or treatment of solid tumor disease, were prepared and formulated. E.g., a multi-step synthesis of I [R1 = OMe; R2 = N-methylpiperidin-4-ylmethoxy; R3 = Cl], starting from Et piperidine-4-carboxylate, was given. Biol. activity of compds. I was tested in 4 tests. Thus, the compds. I showed IC50 of 0.001-10 μ M in in vitro c-Src tyrosine kinase assay.

IT 476160-08-4P, 4-(2-Chloro-5-methoxyanilino)-6-methoxy-7-[2-(4-pyridyloxy)ethoxy]quinazoline 476160-09-5P 476160-10-8P 476160-11-9P 476160-12-0P 476160-13-1P 476160-14-2P 476160-15-3P 476160-27-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 4-anilinoquinazolines as antitumor agents)


RN 476160-08-4 CAPLUS

CN 4-Quinazolinamine, N-(2-chloro-5-methoxyphenyl)-6-methoxy-7-[2-(4-pyridinyloxy)ethoxy] - (9CI) (CA INDEX NAME)




RN 476160-09-5 CAPLUS

CN 4-Quinazolinamine, N-(2-chloro-5-methoxyphenyl)-6-methoxy-7-[3-(4-pyridinyloxy)propoxy] - (9CI) (CA INDEX NAME)




RN 476160-10-8 CAPLUS

CN 4-Quinazolinamine, N-(2-bromo-5-methoxyphenyl)-6-methoxy-7-[2-(4-pyridinyloxy)ethoxy] - (9CI) (CA INDEX NAME)




RN 476160-11-9 CAPLUS

CN 4-Quinazolinamine, N-(2-bromo-5-methoxyphenyl)-6-methoxy-7-[3-(4-pyridinyloxy)propoxy] - (9CI) (CA INDEX NAME)




RN 476160-12-0 CAPLUS

CN 4-Quinazolinamine, N-(2-chloro-5-methoxyphenyl)-6-methoxy-7-[3-(2-pyridinyloxy)propoxy]-(9CI) (CA INDEX NAME)




RN 476160-13-1 CAPLUS

CN 3-Pyridinecarbonitrile, 4-[[[4-[(2-chloro-5-methoxyphenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-(9CI) (CA INDEX NAME)




RN 476160-14-2 CAPLUS

CN 3-Pyridinecarbonitrile, 4-[[[4-[(2-bromo-5-methoxyphenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-(9CI) (CA INDEX NAME)




RN 476160-15-3 CAPLUS

CN 4-Quinazolinamine, N-(2-chloro-5-methoxyphenyl)-6-methoxy-7-[2-[5-methyl-2-(4-morpholinylmethyl)-1H-imidazol-1-yl]ethoxy]- (9CI) (CA INDEX NAME)




RN 476160-27-7 CAPLUS


CN 1(2H)-Pyridineethanol, α-[[[4-[(2-chloro-5-methoxyphenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-3,6-dihydro- (9CI) (CA INDEX NAME)



IT 476156-86-2P, 7-Benzyloxy-4-(2-chloro-5-methoxyanilino)-6-methoxyquinazoline 476160-50-6P, 4-(2-Bromo-5-methoxyanilino)-7-benzyloxy-6-methoxyquinazoline
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 4-anilinoquinazolines as antitumor agents)
RN 476156-86-2 CAPLUS
CN 4-Quinazolinamine, N-(2-chloro-5-methoxyphenyl)-6-methoxy-7-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 476160-50-6 CAPLUS
CN 4-Quinazolinamine, N-(2-bromo-5-methoxyphenyl)-6-methoxy-7-(phenylmethoxy)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L24 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 4
ACCESSION NUMBER: 2001:228864 CAPLUS
DOCUMENT NUMBER: 134:252355
TITLE: Preparation of quinazolines as aurora 2 kinase inhibitors
INVENTOR(S): Mortlock, Andrew Austen; Keen, Nicholas John
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001021594	A1	20010329	WO 2000-GB3556	20000918
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2384282	AA	20010329	CA 2000-2384282	20000918
BR 2000014133	A	20020611	BR 2000-14133	20000918
TR 200200749	T2	20020621	TR 2002-200200749	20000918
EP 1218356	A1	20020703	EP 2000-962677	20000918
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003509497	T2	20030311	JP 2001-524973	20000918
EE 200200149	A	20030415	EE 2002-149	20000918
AU 763242	B2	20030717	AU 2000-74325	20000918
ZA 2002001833	A	20030605	ZA 2002-1833	20020305
BG 106491	A	20021229	BG 2002-106491	20020307
NO 2002001401	A	20020521	NO 2002-1401	20020320
PRIORITY APPLN. INFO.:			GB 1999-22152	A 19990921
			GB 1999-22156	A 19990921
			GB 1999-22159	A 19990921
			WO 2000-GB3556	W 20000918

OTHER SOURCE(S) : MARPAT 134:252355
GI



I



II

AB Title compds. (I) [wherein X = O, S, SO, SO₂, NH, or NR₈; R₈ = H or alkyl; Ra = (un)substituted 3-quinolinyl or Ph; R₁-R₄ = independently halo, CN, NO₂, alkylsulfanyl, N(OH)R₁₂, or R₁₄X₁; R₁₂ = H or alkyl; X₁ = a direct bond, O, CH₂, OC(O), CO, S, SO, SO₂, or (un)substituted NHCO, CONH, SO₂NH, NHSO₂, or NH; R₁₄ = H or (un)substituted hydrocarbyl, heterocyclyl, or alkoxy; or a salt, ester, or amide thereof] were prepared as aurora 2 kinase


inhibitors for the treatment of proliferative diseases, such as cancer. For example, 4-phenoxyaniline•HCl and 4-chloro-6-methoxy-7-(3-morpholinopropoxy)quinazoline were refluxed in i-PrOH to yield II (86%). The latter inhibited the serine/threonine kinase activity of aurora 2 kinase by 50% at a concentration of 0.069 μ M. In addition, II gave 50% inhibition of MCF-7 cell proliferation at 2.89 μ M and reduced BrdU incorporation into cellular DNA by 50% at 3.68 μ M.

IT 330999-51-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-substituted quinazoline aurora 2 kinase inhibitors by coupling quinolinyl or Ph alcs., thiols, or amines with 4-haloquinazolines)

RN 330999-51-4 CAPLUS

CN 4-Quinazolinamine, 6-methoxy-N-(4-phenoxyphenyl)-7-(phenylmethoxy)- (9CI)
(CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 5

ACCESSION NUMBER: 2000:733043 CAPLUS

DOCUMENT NUMBER: 133:281796

TITLE: Method for preparation of anticancer 4-(3-ethynylphenylamino)quinazoline derivatives and intermediates thereof

INVENTOR(S): Lehner, Richard Shelton; Norris, Timothy; Santafianos, Dinos Paul

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: Jpn. Kokai Tokkyo Koho, 15 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
JP 2000290262	A2	20001017	JP 2000-91300	20000329
JP 3420549	B2	20030623		
EP 1044969	A2	20001018	EP 2000-302256	20000320
EP 1044969	A3	20001129		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO

BR 2000001486	A	20010502	BR 2000-1486	20000327
EG 22506	A	20030331	EG 2000-364	20000327
TW 553939	B	20030921	TW 2000-89105605	20000327
BG 104278	A	20010831	BG 2000-104278	20000328
AU 781402	B2	20050519	AU 2000-22620	20000328
CA 2302965	AA	20000930	CA 2000-2302965	20000329
CA 2302965	C	20040217		
CA 2427221	AA	20000930	CA 2000-2427221	20000329
ZA 2000001586	A	20011001	ZA 2000-1586	20000329
JP 2003176274	A2	20030624	JP 2002-360742	20000329
NO 2000001648	A	20001002	NO 2000-1648	20000330
TR 2000000837	A2	20001121	TR 2000-200000837	20000330
EE 200000255	A	20001215	EE 2000-255	20000330
NZ 503683	A	20010928	NZ 2000-503683	20000330
US 6476040	B1	20021105	US 2000-538635	20000330
NZ 512818	A	20030131	NZ 2000-512818	20000330
CN 1276370	A	20001213	CN 2000-104595	20000331
HR 2000000182	A1	20010430	HR 2000-182	20000331
PRIORITY APPLN. INFO.:			US 1999-127072P	P 19990331
			CA 2000-2302965	A3 20000329
			JP 2000-91300	A3 20000329
			NZ 2000-503683	A1 20000330

OTHER SOURCE(S): CASREACT 133:281796; MARPAT 133:281796
GI



I


AB The title compds. [I; G = H; R1, R2 = C1-10 alkyl or alkoxy each optionally substituted by ≤2 groups selected from HO or C1-6 alkoxy; R15 = H, C1-10 alkyl, C6-10 aryl-(CH2)q; q = 0-4], pharmacol. acceptable salts or solvates thereof, which are useful as anticancer agents (no data), are prepared by treatment of I [G = C(OH)R3R4 protecting group; R3, R4 = C1-6 alkyl] with alkali or alkaline earth metal hydroxide in a solvent containing hydroxy-C1-10 group or treatment of I (G = SiR3R4R5 protecting group; R3, R4, R5 = C1-6 alkyl) with tetra(C1-6 alkyl)ammonium fluoride in an aprotic solvent. Thus, 4-chloro-6,7-bis(2-methoxyethoxy)quinazoline was treated with 3-[(trimethylsilyl)ethynyl]aniline in 2-propanol and refluxed for 2.5 h to give 88% I.HCl (G = trimethylsilyl, R1 = R2 = 2-methoxyethoxy, R15 = H) which was stirred with Bu4NF in THF at room temperature for 1 h to give 72% I.HCl (G = R15 = H, R1 = R2 = 2-methoxyethoxy).

IT 299912-65-5P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(method for preparation of anticancer (ethynylphenylamino)quinazoline

derivs. and intermediates thereof)

RN 299912-65-5 CAPLUS

CN 4-Quinazolinamine, 6-(2-methoxyethoxy)-N-(4-methoxyphenyl)-7-(phenylmethoxy) - (9CI) (CA INDEX NAME)



L24 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 6

ACCESSION NUMBER: 1997:640511 CAPLUS

DOCUMENT NUMBER: 127:278209

TITLE: Preparation of 4-anilinoquinazolines for use in the treatment of disease states associated with antiangiogenesis and/or increased vascular permeability

INVENTOR(S): Thomas, Andrew Peter; Hennequin, Laurent Francois Andre; Johnstone, Craig

PATENT ASSIGNEE(S): Zeneca Ltd., UK; Zeneca Pharma S.A.; Thomas, Andrew Peter; Hennequin, Laurent Francois Andre; Johnstone, Craig

SOURCE: PCT Int. Appl., 72 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9732856	A1	19970912	WO 1997-GB550	19970228
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9701747	A	19980827	ZA 1997-1747	19970227
CA 2244897	AA	19970912	CA 1997-2244897	19970228
AU 9718664	A1	19970922	AU 1997-18664	19970228
AU 719327	B2	20000504		
EP 885198	A1	19981223	EP 1997-906814	19970228
EP 885198	B1	20011219		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, FI

CN 1212684	A	19990331	CN 1997-192807	19970228
CN 1116286	B	20030730		
NZ 331191	A	20000327	NZ 1997-331191	19970228
JP 2000517291	T2	20001226	JP 1997-531552	19970228
AT 211134	E	20020115	AT 1997-906814	19970228
PT 885198	T	20020628	PT 1997-906814	19970228
ES 2169355	T3	20020701	ES 1997-906814	19970228
IL 125954	A1	20030624	IL 1997-125954	19970228
TW 542826	B	20030721	TW 1997-86102593	19970304
NO 9804085	A	19980904	NO 1998-4085	19980904
NO 311427	B1	20011126		
US 6291455	B1	20010918	US 1998-142339	19980908
PRIORITY APPLN. INFO.:			EP 1996-400468	A 19960305
			EP 1996-401499	A 19960708
			WO 1997-GB550	W 19970228
OTHER SOURCE(S):		MARPAT 127:278209		
GI				




AB The title compds. [I; R1 = H, MeO; R2 = MeO, EtO, 2-MeO(CH₂)₂O, etc.; R3 = halo, OH, CN, etc.] and their salts, inhibiting the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis, were prepared and formulated. Thus, reaction of 4-chloro-7-(2-methoxyethoxy)quinazoline.HCl with 4-chloro-2-fluoroaniline in iPrOH afforded 84% I [R1 = H; R2 = 2-MeO(CH₂)₂O; R3 = 4-Cl, 2-F]. Compds. I are effective at 1-50 mg/kg.

IT **196603-79-9P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of 4-anilinoquinazolines for use in the treatment of disease states associated with antiangiogenesis and/or increased vascular permeability)

RN 196603-79-9 CAPLUS

CN Phenol, 5-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]-2-methyl-(9CI) (CA INDEX NAME)



L24 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 7



ACCESSION NUMBER: 1997:675952 CAPLUS
 DOCUMENT NUMBER: 127:262698
 TITLE: Preparation of quinazolines as VEGF inhibitors
 INVENTOR(S): Thomas, Andrew Peter; Johnstone, Craig; Hennequin, Laurent Francois Andre
 PATENT ASSIGNEE(S): Zeneca Ltd., UK; Zeneca Pharma S.A.; Thomas, Andrew Peter; Johnstone, Craig; Hennequin, Laurent Francois Andre
 SOURCE: PCT Int. Appl., 102 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9730035	A1	19970821	WO 1997-GB365	19970210
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2242425	AA	19970821	CA 1997-2242425	19970210
AU 9717290	A1	19970902	AU 1997-17290	19970210
AU 719434	B2	20000511		
EP 880508	A1	19981202	EP 1997-904512	19970210
EP 880508	B1	20030416		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CN 1211239	A	19990317	CN 1997-192221	19970210
CN 1125817	B	20031029		
BR 9707495	A	19990727	BR 1997-7495	19970210
NZ 330868	A	20000128	NZ 1997-330868	19970210
JP 2000504714	T2	20000418	JP 1997-529078	19970210
IL 125686	A1	20021110	IL 1997-125686	19970210
RU 2196137	C2	20030110	RU 1998-117074	19970210
CZ 291386	B6	20030212	CZ 1998-2535	19970210
AT 237596	E	20030515	AT 1997-904512	19970210

PT 880508	T	20030731	PT 1997-904512	19970210
ES 2194181	T3	20031116	ES 1997-904512	19970210
ZA 9701180	A	19970813	ZA 1997-1180	19970212
TW 581765	B	20040401	TW 1997-86101670	19970212
NO 9803687	A	19980813	NO 1998-3687	19980812
NO 311359	B1	20011119		
US 6184225	B1	20010206	US 1998-125271	19980813
HK 1016607	A1	20030926	HK 1999-101774	19990421
PRIORITY APPLN. INFO.:			EP 1996-400293	A 19960213
			EP 1996-401756	A 19960808
			EP 1996-402764	A 19961217
			WO 1997-GB365	W 19970210

OTHER SOURCE(S): MARPAT 127:262698

GI




AB The title compds. [I; Z = O, NH, S; m = 1-5; R1 = H, OH, halo, etc.; R2 = H, OH, halo, etc.; R3 = OH, halo, C1-3 alkyl, etc.; X1 = O, CH2, S, etc.; R4 = H, C1-5 alkyl, C1-5 hydroxyalkyl, etc.] and their salts which inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis, were prepared and formulated. Thus, reaction of 4-chloro-6,7-dimethoxyquinazoline with 4-bromo-2-fluoro-5-hydroxyaniline in the presence of isopropanolic hydrogen chloride in 2-butanol afforded 87% quinazoline II.HCl. Compds. I are effective at 1-50 mg/kg.

IT **192999-96-5P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of quinazolines as VEGF inhibitors)

RN 192999-96-5 CAPLUS

CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-(phenylmethoxy)-4-

quinazolinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L24 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:784580 CAPLUS

DOCUMENT NUMBER: 132:151769

TITLE: Design and Structure-Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitors

AUTHOR(S): Hennequin, Laurent F.; Thomas, Andrew P.; Johnstone, Craig; Stokes, Elaine S. E.; Ple, Patrick A.; Lohmann, Jean-Jacques M.; Ogilvie, Donald J.; Dukes, Mike; Wedge, Steve R.; Curwen, Jon O.; Kendrew, Jane; Lambert-van der Brempt, Christine

CORPORATE SOURCE: AstraZeneca Zeneca Pharma Centre de Recherches Z.I. La Pompelle, Reims, 51689, Fr.

SOURCE: Journal of Medicinal Chemistry (1999), 42(26), 5369-5389


CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



I

AB A series of substituted 4-anilinoquinazolines and related compds. were synthesized as potential inhibitors of vascular endothelial growth factor

(VEGF) receptor (Flt and KDR) tyrosine kinase activity. Enzyme screening indicated that a narrow structure-activity relationship (SAR) existed for the bicyclic ring system, with quinazolines, quinolines, and cinnolines having activity and with quinazolines and quinolines generally being preferred. Substitution of the aniline was investigated and clearly indicated that small lipophilic substituents such as halogens or Me were preferred at the C-4' position. Small substituents such as hydrogen and fluorine are preferred at the C-2' position. Introduction of a hydroxyl group at the meta position of the aniline produced the most potent inhibitors of Flt and KDR tyrosine kinases activity with IC₅₀ values in the nanomolar range. Investigation of the quinazoline C-6 and C-7 positions indicates that a large range of substituents are tolerated at C-7, whereas variation at the C-6 is more restricted. At C-7, neutral, basic, and heteroarom. side chains led to very potent compds., as illustrated by the methoxyethoxy derivative I [R₁ = 4-Cl, R₂ = OCH₂CH₂OMe] (IC₅₀ < 2 nM). These inhibitors proved to be very selective inhibitors of Flt and KDR tyrosine kinase activity when compared to that associated with the FGF receptor (50- to 3800-fold). Observed enzyme profiles translated well with respect to potency and selectivity for inhibition of growth factor stimulated proliferation of human umbilical vein endothelial cells (HUVECs). Oral administration of selected compds. to mice produced total plasma levels 6 h after dosing of between 3 and 49 μM. In vivo efficacy was demonstrated in a rat uterine edema assay where significant activity was achieved at 60 mg/kg with I [R₁ = Me, R₂ = OMe]. Inhibition of growth of human tumors in athymic mice has also been demonstrated: I [R₁ = Br, R₂ = 2-(1,2,3-triazol-1-yl)ethoxy] inhibited the growth of established Calu-6 lung carcinoma xenograft by 75% (P < 0.001, one tailed t-test) following daily oral administration of 100 mg/kg for 21 days.


IT 192999-96-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and structure-activity relationship of arylaminoquinazoline VEGF receptor tyrosine kinase inhibitors)

RN 192999-96-5 CAPLUS

CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]aminol]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT:

79

THERE ARE 79 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:502972 CAPLUS

DOCUMENT NUMBER: 127:135808

TITLE: Preparation and antiangiogenic and/or vascular permeability reducing effect of quinazoline derivatives

INVENTOR(S): Lohmann, Jean-Jacques Marcel; Hennequin, Laurent Francois Andre; Thomas, Andrew Peter

PATENT ASSIGNEE(S): Zeneca Limited, UK; Zeneca-Pharma S.A.; Lohmann, Jean-Jacques Marcel; Hennequin, Laurent Francois Andre; Thomas, Andrew Peter

SOURCE: PCT Int. Appl., 162 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9722596	A1	19970626	WO 1996-GB3075	19961213
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2237005	AA	19970626	CA 1996-2237005	19961213
AU 9711061	A1	19970714	AU 1997-11061	19961213
AU 712370	B2	19991104		
EP 873319	A1	19981028	EP 1996-941787	19961213
EP 873319	B1	20010725		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CN 1205694	A	19990120	CN 1996-199110	19961213
CN 1133625	B	20040107		
BR 9612043	A	19991228	BR 1996-12043	19961213
JP 2000515114	T2	20001114	JP 1997-522568	19961213
AT 203524	E	20010815	AT 1996-941787	19961213
ES 2162656	T3	20020101	ES 1996-941787	19961213
PT 873319	T	20020130	PT 1996-941787	19961213
SK 282443	B6	20020205	SK 1998-828	19961213
CZ 291100	B6	20021211	CZ 1998-1882	19961213
RU 2194701	C2	20021220	RU 1998-113300	19961213
ZA 9610597	A	19970618	ZA 1996-10597	19961217
US 5962458	A	19991005	US 1996-768887	19961217
TW 411274	B	20001111	TW 1996-85115569	19961217
NO 9802784	A	19980817	NO 1998-2784	19980617
NO 311358	B1	20011119		
US 6071921	A	20000606	US 1998-203764	19981202
US 6258951	B1	20010710	US 2000-500470	20000209
US 2002032208	A1	20020314	US 2001-877005	20010611
US 6362336	B2	20020326		
GR 3036954	T3	20020131	GR 2001-401823	20011019
PRIORITY APPLN. INFO.:			EP 1995-402846	A 19951218
			EP 1996-402190	A 19961015

EP 1996-941787	A 19961213
WO 1996-GB3075	W 19961213
US 1996-768887	A1 19961217
US 1998-203764	A1 19981202
US 2000-500470	A3 20000209

OTHER SOURCE(S) : MARPAT 127:135808
GI



AB Quinazoline derivs. I [Y1 represents -O-, -S-, -CH2-, -SO-, -SO2-, NR5CO-, -CONR6-, -SO2NR7-, -NR8SO2- or -NR9- (wherein R5, R6, R7, R8 and R9 each independently represents hydrogen, alkyl or alkoxyalkyl); R1 represents hydrogen, hydroxy, halo, nitro, trifluoromethyl, cyano, alkyl, alkoxy, alkylthio, amino, alkylamino; R2 represents hydrogen, hydroxy, halo, alkyl, alkoxy, trifluoromethyl, cyano, amino, nitro; m is an integer from 1 to 5; R3 represents hydroxy, halo, alkyl, alkoxy, alkanoyloxy, trifluoromethyl, cyano, amino, nitro; R4 represents a group which is or which contains an optionally substituted pyridone, Ph or aromatic heterocyclic group] were prepared I inhibit the effects of VEGF (no data), a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis. E.g., heating a mixture of 2-amino-4-benzyloxy-5-methoxybenzamide and Gold's reagent, followed by NaOAc and HOAc, gave 7-benzyloxy-6-methoxy-3,4-dihydroquinazolin-4-one. The product was treated with thionyl chloride, then 3-acetoxy-4-methylaniline, and next hydrogenolyzed to give 4-(3-acetoxy-4-methylanilino)-7-hydroxy-6-methoxyquinazoline hydrochloride. The last was reacted with 4-(bromomethyl)pyridine hydrobromide and treated with aqueous NaOH to give 4-(3-hydroxy-4-methylanilino)-6-methoxy-7-(4-pyridylmethoxy)quinazoline hydrochloride.

IT 192999-68-1P 192999-70-5P 192999-71-6P
192999-72-7P 192999-73-8P 192999-74-9P
192999-75-0P 192999-76-1P 192999-77-2P
192999-78-3P 192999-79-4P 192999-80-7P
192999-81-8P 192999-88-5P 192999-89-6P
192999-90-9P 192999-94-3P 192999-95-4P
192999-96-5P 192999-98-7P 192999-99-8P
193000-00-9P 193000-01-0P 193000-02-1P
193000-03-2P 193000-10-1P 193000-26-9P
193000-27-0P 193000-39-4P 193000-40-7P
193000-41-8P 193000-42-9P 193000-43-0P
193000-44-1P 193000-45-2P 193000-46-3P
193000-47-4P 193000-59-8P 193000-76-9P
193000-77-0P 193000-78-1P 193000-79-2P
193000-80-5P 193000-81-6P 193000-82-7P


193000-83-8P 193000-84-9P 193000-85-0P
 193000-86-1P 193000-87-2P 193000-88-3P
 193000-89-4P 193000-90-7P 193000-91-8P
 193000-92-9P 193000-93-0P 193000-94-1P
 193000-96-3P 193000-97-4P 193000-98-5P
 193000-99-6P 193001-00-2P 193001-01-3P
 193001-02-4P 193001-03-5P 193001-04-6P
 193001-06-8P 193001-09-1P 193001-14-8P
 193001-16-0P 193001-18-2P 193001-32-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and antiangiogenic and/or vascular permeability reducing effect of quinazoline derivs.)

RN 192999-68-1 CAPLUS


CN Phenol, 5-[[6-methoxy-7-(4-pyridinylmethoxy)-4-quinazolinyl]amino]-2-methyl-, hydrochloride (5:1) (9CI) (CA INDEX NAME)



● 1/5 HCl


RN 192999-70-5 CAPLUS

CN Phenol, 5-[[6-methoxy-7-(3-pyridinylmethoxy)-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 192999-71-6 CAPLUS


CN Phenol, 5-[[6-methoxy-7-(2-pyridinylmethoxy)-4-quinazolinyl]amino]-2-methyl-, hydrochloride (4:3) (9CI) (CA INDEX NAME)



● 3/4 HCl


RN 192999-72-7 CAPLUS

CN Phenol, 5-[[6-methoxy-7-(4-pyrimidinylmethoxy)-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 192999-73-8 CAPLUS


CN Phenol, 5-[[6-methoxy-7-[(1-methyl-1H-imidazol-2-yl)methoxy]-4-quinazolinyl]amino]-2-methyl-, hydrochloride (10:19) (9CI) (CA INDEX NAME)



●19/10 HCl

RN 192999-74-9 CAPLUS


CN Phenol, 5-[[6-methoxy-7-[(2-methyl-4-thiazolyl)methoxy]-4-quinazolinyl]amino]-2-methyl-, hydrochloride (10:17) (9CI) (CA INDEX NAME)



●17/10 HCl


RN 192999-75-0 CAPLUS

CN Phenol, 5-[[6-methoxy-7-(3-thienylmethoxy)-4-quinazolinyl]amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 192999-76-1 CAPLUS
 CN Acetamide, N-[4-[[[4-[(3-hydroxy-4-methylphenyl)amino]-6-methoxy-7-quinazolinyl]oxy)methyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 192999-77-2 CAPLUS
 CN Phenol, 5-[[7-[(3,5-dimethyl-4-isoxazolyl)methoxy]-6-methoxy-4-quinazolinyl]amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 192999-78-3 CAPLUS


CN Phenol, 5-[[6-methoxy-7-[3-(4-pyridinyl)propoxy]-4-quinazolinyl]amino]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 192999-79-4 CAPLUS

CN Phenol, 4-fluoro-5-[[6-methoxy-7-[3-(4-pyridinyl)propoxy]-4-quinazolinyl]amino]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 192999-80-7 CAPLUS
 CN Phenol, 4-fluoro-5-[[6-methoxy-7-(4-pyridinylmethoxy)-4-quinazolinyl]amino]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 192999-81-8 CAPLUS
 CN Phenol, 4-fluoro-5-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 192999-88-5 CAPLUS

CN Phenol, 4-fluoro-5-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]oxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 192999-89-6 CAPLUS


CN Phenol, 4-fluoro-5-[[6-methoxy-7-[(2-methyl-4-thiazolyl)methoxy]-4-quinazolinyl]amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 192999-90-9 CAPLUS


CN Phenol, 4-fluoro-2-methyl-5-[[7-(4-pyridinylmethoxy)-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 192999-94-3 CAPLUS


CN Phenol, 4-fluoro-5-[[6-methoxy-7-[(1-methyl-1H-imidazol-2-yl)methoxy]-4-quinazolinyl]amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 192999-95-4 CAPLUS


CN Acetamide, N-[4-[[[4-[(2-fluoro-5-hydroxy-4-methylphenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 192999-96-5 CAPLUS

CN Phenol, 2-chloro-4-fluoro-5-[[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 192999-98-7 CAPLUS
 CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-[3-(4-pyridinyl)propoxy]-4-quinazolinyl]amino]-, hydrochloride (10:19) (9CI) (CA INDEX NAME)




● 19/10 HCl

RN 192999-99-8 CAPLUS
 CN Phenol, 4-fluoro-5-[[7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino]-2-methyl-, hydrochloride (10:19) (9CI) (CA INDEX NAME)




●19/10 HCl

RN 193000-00-9 CAPLUS
 CN Phenol, 2-chloro-4-fluoro-5-[[7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 193000-01-0 CAPLUS
 CN Phenol, 4-fluoro-5-[[6-methoxy-7-[2-(4-pyridinyl)ethoxy]-4-quinazolinyl]amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 193000-02-1 CAPLUS
 CN Phenol, 4-fluoro-5-[[[6-methoxy-7-(3-thienylmethoxy)-4-quinazolinyl]amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 193000-03-2 CAPLUS
 CN Benzonitrile, 4-[[[4-[(2-fluoro-5-hydroxy-4-methylphenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 193000-10-1 CAPLUS
 CN Phenol, 5-[[7-[(2-chloro-6-methyl-4-pyridinyl)methoxy]-6-methoxy-4-quinazolinyl]amino]-4-fluoro-2-methyl-, hydrochloride (10:19) (9CI) (CA INDEX NAME)




● 19/10 HCl

RN 193000-26-9 CAPLUS
 CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-(4-pyridinylmethoxy)-4-quinazolinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 193000-27-0 CAPLUS
 CN Phenol, 5-[[7-[(2-chloro-4-pyridinyl)methoxy]-6-methoxy-4-quinazolinyl]amino]-4-fluoro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 193000-39-4 CAPLUS
 CN Phenol, 4-fluoro-2-methyl-5-[[7-(phenylmethoxy)-4-quinazolinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 193000-40-7 CAPLUS
 CN Phenol, 2-chloro-4-fluoro-5-[[7-(benzyloxy)-4-quinazolinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 193000-41-8 CAPLUS
 CN Phenol, 5-[[7-[(3,4-difluorophenyl)methoxy]-6-methoxy-4-quinazolinyl]amino]-4-fluoro-2-methyl-, hydrochloride (10:9) (9CI) (CA INDEX NAME)




● 9/10 HCl

RN 193000-42-9 CAPLUS
 CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-[(1-methyl-1H-imidazol-2-yl)methoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 193000-43-0 CAPLUS
 CN Phenol, 4-fluoro-2-methyl-5-[[7-[(1-methyl-1H-imidazol-2-yl)methoxy]-4-quinazolinyl]amino]-, hydrochloride (5:9) (9CI) (CA INDEX NAME)



● 9/5 HCl

RN 193000-44-1 CAPLUS


CN Phenol, 4-fluoro-5-[[6-methoxy-7-[2-(1H-1,2,4-triazol-1-yl)ethoxy]-4-quinazolinyl]amino]-2-methyl-, hydrochloride (5:6) (9CI) (CA INDEX NAME)



● 6/5 HCl

RN 193000-45-2 CAPLUS


CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-(3-thienylmethoxy)-4-quinazolinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 193000-46-3 CAPLUS


CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-[2-(4-pyridinyl)ethoxy]-4-quinazolinyl]amino]-, hydrochloride (5:9) (9CI) (CA INDEX NAME)



● 9/5 HCl

RN 193000-47-4 CAPLUS


CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-[(2-methyl-4-thiazolyl)methoxy]-4-quinazolinyl]amino]-, hydrochloride (5:6) (9CI) (CA INDEX NAME)



●6/5 HCl

RN 193000-59-8 CAPLUS


CN Phenol, 3-[[7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino]-, hydrochloride (10:19) (9CI) (CA INDEX NAME)



●19/10 HCl


RN 193000-76-9 CAPLUS

CN Phenol, 5-[[6-methoxy-7-(4-pyridinylmethoxy)-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-77-0 CAPLUS

CN Phenol, 5-[[6-methoxy-7-(2-pyridinylmethoxy)-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-78-1 CAPLUS

CN Phenol, 5-[[6-methoxy-7-[(1-methyl-1H-imidazol-2-yl)methoxy]-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-79-2 CAPLUS

CN Phenol, 5-[[6-methoxy-7-[(2-methyl-4-thiazolyl)methoxy]-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-80-5 CAPLUS

CN Acetamide, N-[4-[[[4-[(3-hydroxy-4-methylphenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 193000-81-6 CAPLUS

CN Phenol, 5-[[[6-methoxy-7-[3-(4-pyridinyl)propoxy]-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-82-7 CAPLUS

CN Phenol, 4-fluoro-5-[[[6-methoxy-7-[3-(4-pyridinyl)propoxy]-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-83-8 CAPLUS

CN Phenol, 4-fluoro-5-[[6-methoxy-7-(4-pyridinylmethoxy)-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-84-9 CAPLUS

CN Phenol, 4-fluoro-5-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-85-0 CAPLUS

CN Phenol, 4-fluoro-5-[[6-methoxy-7-[(2-methyl-4-thiazolyl)methoxy]-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-86-1 CAPLUS

CN Phenol, 4-fluoro-2-methyl-5-[[7-(4-pyridinylmethoxy)-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)




RN 193000-87-2 CAPLUS

CN Phenol, 4-fluoro-5-[[6-methoxy-7-[(1-methyl-1H-imidazol-2-yl)methoxy]-4-quinazolinyl]amino]-2-methyl-(9CI) (CA INDEX NAME)




RN 193000-88-3 CAPLUS

CN Acetamide, N-[[4-[[[4-[(2-fluoro-5-hydroxy-4-methylphenyl)amino]-6-methoxy-7-quinazolinyl]oxy)methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 193000-89-4 CAPLUS

CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]oxy]- (9CI) (CA INDEX NAME)




RN 193000-90-7 CAPLUS

CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-[3-(4-pyridinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 193000-91-8 CAPLUS

CN Phenol, 4-fluoro-5-[[7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-92-9 CAPLUS

CN Phenol, 2-chloro-4-fluoro-5-[[7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 193000-93-0 CAPLUS

CN Phenol, 4-fluoro-5-[[6-methoxy-7-[2-(4-pyridinyl)ethoxy]-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-94-1 CAPLUS

CN Phenol, 4-fluoro-5-[[6-methoxy-7-(3-thienylmethoxy)-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-96-3 CAPLUS

CN Phenol, 5-[[7-[(2-chloro-6-methyl-4-pyridinyl)methoxy]-6-methoxy-4-quinazolinyl]amino]-4-fluoro-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-97-4 CAPLUS

CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-(4-pyridinylmethoxy)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 193000-98-5 CAPLUS

CN Phenol, 5-[[7-[(2-chloro-4-pyridinyl)methoxy]-6-methoxy-4-quinazolinyl]amino]-4-fluoro-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-99-6 CAPLUS

CN Phenol, 5-[[7-[(3,4-difluorophenyl)methoxy]-6-methoxy-4-quinazolinyl]amino]-4-fluoro-2-methyl- (9CI) (CA INDEX NAME)




RN 193001-00-2 CAPLUS

CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-[(1-methyl-1H-imidazol-2-yl)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 193001-01-3 CAPLUS

CN Phenol, 4-fluoro-2-methyl-5-[[7-[(1-methyl-1H-imidazol-2-yl)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 193001-02-4 CAPLUS

CN Phenol, 4-fluoro-2-methyl-5-[[7-[2-(1H-1,2,4-triazol-1-yl)ethoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 193001-03-5 CAPLUS

CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-(3-thienylmethoxy)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 193001-04-6 CAPLUS

CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-[2-(4-pyridinyl)ethoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 193001-06-8 CAPLUS

CN Phenol, 5-[[6-methoxy-7-(3-thienylmethoxy)-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193001-09-1 CAPLUS

CN Benzonitrile, 4-[[[4-[(2-fluoro-5-hydroxy-4-methylphenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 193001-14-8 CAPLUS

CN Phenol, 4-fluoro-2-methyl-5-[[[7-(phenylmethoxy)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 193001-16-0 CAPLUS

CN Phenol, 2-chloro-4-fluoro-5-[[[7-(phenylmethoxy)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 193001-18-2 CAPLUS

CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-[(2-methyl-4-thiazolyl)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 193001-32-0 CAPLUS

CN Phenol, 3-[[7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



L24 ANSWER 9 OF 15 USPATFULL on STN

DUPLICATE 3

ACCESSION NUMBER: 2002:55045 USPATFULL

TITLE: Chemical compounds

INVENTOR(S): Lohmann, Jean-Jacques Marcel, Merfy, FRANCE
Hennequin, Laurent Francois Andre, Champigny sur
Vesles, FRANCEPATENT ASSIGNEE(S): Thomas, Andrew Peter, Congleton, UNITED KINGDOM
ZENECA LIMITED (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002032208	A1	20020314
	US 6362336	B2	20020326
APPLICATION INFO.:	US 2001-877005	A1	20010611 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-500470, filed on 9 Feb 2000, GRANTED, Pat. No. US 6258951 Continuation of Ser. No. US 1998-203764, filed on 2 Dec 1998, GRANTED, Pat. No. US 6071921 Continuation of Ser. No. US 1996-768887, filed on 17 Dec 1996, GRANTED, Pat. No. US 5962458		

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1995-402846	19951218
	EP 1996-402190	19961015
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Pillsbury Winthrop LLP, Intellectual Property Group, East Tower, Ninth Floor, 1100 New York Avenue, N.W., Washington, DC, 20005-3918	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
LINE COUNT:	5568	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to quinazoline derivatives of the formula:
##STR1##

[wherein:

Y.sup.1 represents --O--, --S--, --CH.sub.2--, --SO--, --SO.sub.2--, --NR.sup.5CO--, --CONR.sup.6--, --SO.sub.2NR.sup.7--, --NR.sup.8SO.sub.2-- or --NR.sup.9-- (wherein R.sup.5, R.sup.6, R.sup.7, R.sup.8 and R.sup.9 each independently represents hydrogen, alkyl or alkoxyalkyl);

R.sup.1 represents hydrogen, hydroxy, halogeno, nitro, trifluoromethyl, cyano, alkyl, alkoxy, alkylthio, amino or alkylamino.

R.sup.2 represents hydrogen, hydroxy, halogeno, alkyl, alkoxy, trifluoromethyl, cyano, amino or nitro;

m is an integer from 1 to 5;

R.sup.3 represents hydroxy, halogeno, alkyl, alkoxy, alkanoyloxy, trifluoromethyl, cyano, amino or nitro;

R.sup.4 represents a group which is or which contains an optionally substituted pyridone, phenyl or aromatic heterocyclic group] and salts thereof; processes for their preparation and pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient.

The compounds of formula I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 192999-68-1P 192999-70-5P 192999-71-6P
 192999-72-7P 192999-73-8P 192999-74-9P
 192999-75-0P 192999-76-1P 192999-77-2P
 192999-78-3P 192999-79-4P 192999-80-7P
 192999-81-8P 192999-88-5P 192999-89-6P
 192999-90-9P 192999-94-3P 192999-95-4P
 192999-96-5P 192999-98-7P 192999-99-8P
 193000-00-9P 193000-01-0P 193000-02-1P
 193000-03-2P 193000-10-1P 193000-26-9P
 193000-27-0P 193000-39-4P 193000-40-7P
 193000-41-8P 193000-42-9P 193000-43-0P
 193000-44-1P 193000-45-2P 193000-46-3P

193000-47-4P 193000-59-8P 193000-76-9P
193000-77-0P 193000-78-1P 193000-79-2P
193000-80-5P 193000-81-6P 193000-82-7P
193000-83-8P 193000-84-9P 193000-85-0P
193000-86-1P 193000-87-2P 193000-88-3P
193000-89-4P 193000-90-7P 193000-91-8P
193000-92-9P 193000-93-0P 193000-94-1P
193000-96-3P 193000-97-4P 193000-98-5P
193000-99-6P 193001-00-2P 193001-01-3P
193001-02-4P 193001-03-5P 193001-04-6P
193001-06-8P 193001-09-1P 193001-14-8P
193001-16-0P 193001-18-2P 193001-32-0P

(preparation and antiangiogenic and/or vascular permeability reducing effect of quinazoline derivs.)

RN 192999-68-1 USPATFULL


CN Phenol, 5-[[6-methoxy-7-(4-pyridinylmethoxy)-4-quinazolinyl]amino]-2-methyl-, hydrochloride (5:1) (9CI) (CA INDEX NAME)



● 1/5 HCl


RN 192999-70-5 USPATFULL

CN Phenol, 5-[[6-methoxy-7-(3-pyridinylmethoxy)-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 192999-71-6 USPATFULL


CN Phenol, 5-[[6-methoxy-7-(2-pyridinylmethoxy)-4-quinazolinyl]amino]-2-methyl-, hydrochloride (4:3) (9CI) (CA INDEX NAME)



● 3/4 HCl


RN 192999-72-7 USPATFULL

CN Phenol, 5-[[6-methoxy-7-(4-pyrimidinylmethoxy)-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 192999-73-8 USPATFULL


CN Phenol, 5-[[6-methoxy-7-[(1-methyl-1H-imidazol-2-yl)methoxy]-4-quinazolinyl]amino]-2-methyl-, hydrochloride (10:19) (9CI) (CA INDEX NAME)



●19/10 HCl

RN 192999-74-9 USPATFULL


CN Phenol, 5-[[6-methoxy-7-[(2-methyl-4-thiazolyl)methoxy]-4-quinazolinyl]amino]-2-methyl-, hydrochloride (10:17) (9CI) (CA INDEX NAME)



●17/10 HCl

RN 192999-75-0 USPATFULL


CN Phenol, 5-[[6-methoxy-7-(3-thienylmethoxy)-4-quinazolinyl]amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 192999-76-1 USPATFULL


CN Acetamide, N-[4-[[[4-[(3-hydroxy-4-methylphenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 192999-77-2 USPATFULL


CN Phenol, 5-[[7-[(3,5-dimethyl-4-isoxazolyl)methoxy]-6-methoxy-4-quinazolinyl]amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 192999-78-3 USPATFULL


CN Phenol, 5-[[6-methoxy-7-[3-(4-pyridinyl)propoxy]-4-quinazolinyl]amino]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 192999-79-4 USPATFULL


CN Phenol, 4-fluoro-5-[[6-methoxy-7-[3-(4-pyridinyl)propoxy]-4-quinazolinyl]amino]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 192999-80-7 USPATFULL


CN Phenol, 4-fluoro-5-[[6-methoxy-7-(4-pyridinylmethoxy)-4-quinazolinyl]amino]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 192999-81-8 USPATFULL


CN Phenol, 4-fluoro-5-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 192999-88-5 USPATFULL

CN Phenol, 4-fluoro-5-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]oxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 192999-89-6 USPATFULL


CN Phenol, 4-fluoro-5-[[6-methoxy-7-[(2-methyl-4-thiazolyl)methoxy]-4-quinazolinyl]amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 192999-90-9 USPATFULL


CN Phenol, 4-fluoro-2-methyl-5-[[7-(4-pyridinylmethoxy)-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 192999-94-3 USPATFULL


CN Phenol, 4-fluoro-5-[[6-methoxy-7-[(1-methyl-1H-imidazol-2-yl)methoxy]-4-quinazolinyl]amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 192999-95-4 USPATFULL


CN Acetamide, N-[4-[[[4-[(2-fluoro-5-hydroxy-4-methylphenyl)amino]-6-methoxy-7-quinazolinyl]oxy)methyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 192999-96-5 USPATFULL


CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 192999-98-7 USPATFULL


CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-[3-(4-pyridinyl)propoxy]-4-quinazolinyl]amino]-, hydrochloride (10:19) (9CI) (CA INDEX NAME)



●19/10 HCl

RN 192999-99-8 USPATFULL


CN Phenol, 4-fluoro-5-[[7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino]-2-methyl-, hydrochloride (10:19) (9CI) (CA INDEX NAME)



●19/10 HCl

RN 193000-00-9 USPATFULL


CN Phenol, 2-chloro-4-fluoro-5-[[7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 193000-01-0 USPATFULL


CN Phenol, 4-fluoro-5-[[6-methoxy-7-[2-(4-pyridinyl)ethoxy]-4-quinazolinyl]amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 193000-02-1 USPATFULL


CN Phenol, 4-fluoro-5-[[6-methoxy-7-(3-thienylmethoxy)-4-quinazolinyl]amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 193000-03-2 USPATFULL

CN Benzonitrile, 4-[[[4-[(2-fluoro-5-hydroxy-4-methylphenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 193000-10-1 USPATFULL
 CN Phenol, 5-[[7-[(2-chloro-6-methyl-4-pyridinyl)methoxy]-6-methoxy-4-quinazolinyl]amino]-4-fluoro-2-methyl-, hydrochloride (10:19) (9CI) (CA INDEX NAME)



●19/10 HCl


RN 193000-26-9 USPATFULL
 CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-(4-pyridinylmethoxy)-4-quinazolinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 193000-27-0 USPATFULL


CN Phenol, 5-[[7-[(2-chloro-4-pyridinyl)methoxy]-6-methoxy-4-quinazolinyl]amino]-4-fluoro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 193000-39-4 USPATFULL


CN Phenol, 4-fluoro-2-methyl-5-[[7-(phenylmethoxy)-4-quinazolinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 193000-40-7 USPATFULL


CN Phenol, 2-chloro-4-fluoro-5-[[7-(benzylmethoxy)-4-quinazolinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 193000-41-8 USPATFULL


CN Phenol, 5-[[7-[(3,4-difluorophenyl)methoxy]-6-methoxy-4-quinazolinyl]amino]-4-fluoro-2-methyl-, hydrochloride (10:9) (9CI) (CA INDEX NAME)



● 9/10 HCl

RN 193000-42-9 USPATFULL


CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-[(1-methyl-1H-imidazol-2-yl)methoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 193000-43-0 USPATFULL


CN Phenol, 4-fluoro-2-methyl-5-[[7-[(1-methyl-1H-imidazol-2-yl)methoxy]-4-quinazolinyl]amino]-, hydrochloride (5:9) (9CI) (CA INDEX NAME)



●9/5 HCl

RN 193000-44-1 USPATFULL


CN Phenol, 4-fluoro-5-[[6-methoxy-7-[2-(1H-1,2,4-triazol-1-yl)ethoxy]-4-quinazolinyl]amino]-2-methyl-, hydrochloride (5:6) (9CI) (CA INDEX NAME)



●6/5 HCl

RN 193000-45-2 USPATFULL


CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-(3-thienylmethoxy)-4-quinazolinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 193000-46-3 USPATFULL


CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-[2-(4-pyridinyl)ethoxy]-4-quinazolinyl]amino]-, hydrochloride (5:9) (9CI) (CA INDEX NAME)



● 9/5 HCl


RN 193000-47-4 USPATFULL

CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-[(2-methyl-4-thiazolyl)methoxy]-4-quinazolinyl]amino]-, hydrochloride (5:6) (9CI) (CA INDEX NAME)



●6/5 HCl


RN 193000-59-8 USPATFULL

CN Phenol, 3-[[7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino]-
, hydrochloride (10:19) (9CI) (CA INDEX NAME)

●19/10 HCl


RN 193000-76-9 USPATFULL

CN Phenol, 5-[[6-methoxy-7-(4-pyridinylmethoxy)-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-77-0 USPATFULL

CN Phenol, 5-[[6-methoxy-7-(2-pyridinylmethoxy)-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-78-1 USPATFULL

CN Phenol, 5-[[6-methoxy-7-[(1-methyl-1H-imidazol-2-yl)methoxy]-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-79-2 USPATFULL

CN Phenol, 5-[[6-methoxy-7-[(2-methyl-4-thiazolyl)methoxy]-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-80-5 USPATFULL

CN Acetamide, N-[4-[[[4-[(3-hydroxy-4-methylphenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 193000-81-6 USPATFULL

CN Phenol, 5-[[6-methoxy-7-[3-(4-pyridinyl)propoxy]-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-82-7 USPATFULL

CN Phenol, 4-fluoro-5-[[6-methoxy-7-[3-(4-pyridinyl)propoxy]-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-83-8 USPATFULL

CN Phenol, 4-fluoro-5-[[6-methoxy-7-(4-pyridinylmethoxy)-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-84-9 USPATFULL

CN Phenol, 4-fluoro-5-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-85-0 USPATFULL

CN Phenol, 4-fluoro-5-[[6-methoxy-7-[(2-methyl-4-thiazolyl)methoxy]-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-86-1 USPATFULL

CN Phenol, 4-fluoro-2-methyl-5-[[7-(4-pyridinylmethoxy)-4-quinazolinyl]amino] -
(9CI) (CA INDEX NAME)




RN 193000-87-2 USPATFULL

CN Phenol, 4-fluoro-5-[[6-methoxy-7-[(1-methyl-1H-imidazol-2-yl)methoxy]-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-88-3 USPATFULL

CN Acetamide, N-[4-[[[4-[(2-fluoro-5-hydroxy-4-methylphenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 193000-89-4 USPATFULL

CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]oxy]- (9CI) (CA INDEX NAME)




RN 193000-90-7 USPATFULL

CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-[3-(4-pyridinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 193000-91-8 USPATFULL

CN Phenol, 4-fluoro-5-[[7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-92-9 USPATFULL

CN Phenol, 2-chloro-4-fluoro-5-[[7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 193000-93-0 USPATFULL

CN Phenol, 4-fluoro-5-[[6-methoxy-7-[2-(4-pyridinyl)ethoxy]-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-94-1 USPATFULL

CN Phenol, 4-fluoro-5-[[6-methoxy-7-(3-thienylmethoxy)-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-96-3 USPATFULL

CN Phenol, 5-[[7-[(2-chloro-6-methyl-4-pyridinyl)methoxy]-6-methoxy-4-quinazolinyl]amino]-4-fluoro-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-97-4 USPATFULL

CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-(4-pyridinylmethoxy)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 193000-98-5 USPATFULL

CN Phenol, 5-[[7-[(2-chloro-4-pyridinyl)methoxy]-6-methoxy-4-quinazolinyl]amino]-4-fluoro-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-99-6 USPATFULL

CN Phenol, 5-[[7-[(3,4-difluorophenyl)methoxy]-6-methoxy-4-quinazolinyl]amino]-4-fluoro-2-methyl- (9CI) (CA INDEX NAME)




RN 193001-00-2 USPATFULL

CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-[(1-methyl-1H-imidazol-2-yl)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 193001-01-3 USPTAFULL

CN Phenol, 4-fluoro-2-methyl-5-[[7-[(1-methyl-1H-imidazol-2-yl)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 193001-02-4 USPTAFULL

CN Phenol, 4-fluoro-2-methyl-5-[[7-[2-(1H-1,2,4-triazol-1-yl)ethoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 193001-03-5 USPATFULL

CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-(3-thienylmethoxy)-4-quinazolinyl]amino] - (9CI) (CA INDEX NAME)




RN 193001-04-6 USPATFULL

CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-[2-(4-pyridinyl)ethoxy]-4-quinazolinyl]amino] - (9CI) (CA INDEX NAME)




RN 193001-06-8 USPATFULL

CN Phenol, 5-[[6-methoxy-7-(3-thienylmethoxy)-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193001-09-1 USPATFULL

CN Benzonitrile, 4-[[[4-[(2-fluoro-5-hydroxy-4-methylphenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 193001-14-8 USPATFULL

CN Phenol, 4-fluoro-2-methyl-5-[[7-(phenylmethoxy)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 193001-16-0 USPATFULL

CN Phenol, 2-chloro-4-fluoro-5-[[7-(phenylmethoxy)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 193001-18-2 USPATFULL

CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-[(2-methyl-4-thiazolyl)methoxy]-4-quinazolinyl]amino] - (9CI) (CA INDEX NAME)



RN 193001-32-0 USPATFULL

CN Phenol, 3-[[7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino] - (9CI) (CA INDEX NAME)



L24 ANSWER 10 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2002:290948 USPATFULL

TITLE: Processes and intermediates for preparing anti-cancer compounds

INVENTOR(S): Norris, Timothy, Gales Ferry, CT, United States
Santafianos, Dinos P., Groton, CT, United States
Lehner, Richard S., Ledyard, CT, United StatesPATENT ASSIGNEE(S): Pfizer Inc., New York, NY, United States (U.S. corporation)
Pfizer Products Inc., Groton, CT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6476040	B1	20021105
APPLICATION INFO.:	US 2000-538635		20000330 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-127072P	19990331 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: GRANTED
 PRIMARY EXAMINER: Shah, Mukund J.
 ASSISTANT EXAMINER: Truong, Tamthom N.
 LEGAL REPRESENTATIVE: Ladas & Parry
 NUMBER OF CLAIMS: 17
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
 LINE COUNT: 945

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods and intermediates for preparing compounds of the formula 1 ##STR1##

and the pharmaceutically acceptable salts and solvates thereof, as well as structurally related compounds, wherein R.sup.1, R.sup.2 and R.sup.15 are as defined herein. The foregoing compounds are useful in the treatment of hyperproliferative disorders, such as cancers, in mammals.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 299912-65-5P

(method for preparation of anticancer (ethynylphenylamino)quinazoline derivs. and intermediates thereof)

RN 299912-65-5 USPATFULL

CN 4-Quinazolinamine, 6-(2-methoxyethoxy)-N-(4-methoxyphenyl)-7-(phenylmethoxy)- (9CI) (CA INDEX NAME)



L24 ANSWER 11 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2001:158278 USPATFULL

TITLE: 4-anilinoquinazoline derivatives

INVENTOR(S): Thomas, Andrew Peter, Macclesfield, United Kingdom
 Johnstone, Craig, Macclesfield, United Kingdom
 Hennequin, Laurent Francois Andre, Reims Cedex, France
 PATENT ASSIGNEE(S): Zeneca Limited, London, United Kingdom (non-U.S. corporation)
 Zeneca Pharma S.A., Cergy Cedex, France (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6291455	B1	20010918
	WO 9732856		19970912
APPLICATION INFO.:	US 1998-142339		19980908 (9)

WO 1997-GB550

19970228

19980908 PCT 371 date

19980908 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1996-400468	19960305
	EP 1996-401499	19960708
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Raymond, Richard L.	
ASSISTANT EXAMINER:	Balasubramanian, Venkataraman	
LEGAL REPRESENTATIVE:	Pillsbury Winthrop LLP	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2457	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to quinazoline derivatives of formula (I) (wherein: R.sup.1 represents hydrogen or methoxy; R.sup.2 represents methoxy, ethoxy, 2-methoxyethoxy, 3-methoxypropoxy, 2-ethoxyethoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, 2-hydroxyethoxy, 3-hydroxypropoxy, 2-(N,N-dimethylamino)ethoxy, 3-(N,N-dimethylamino)propoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 4-morpholinobutoxy, 2-piperidinoethoxy, 3-piperidinopropoxy, 4-piperidinobutoxy, 2-(piperazin-1-yl)ethoxy, 3-(piperazin-1-yl)propoxy, 4-(piperazin-1-yl)butoxy, 2-(4-methylpiperazin-1-yl)ethoxy, 3-(4-methylpiperazin-1-yl)propoxy or 4-(4-methylpiperazin-1-yl)butoxy; the phenyl group bearing (R.sup.3).sub.2 is selected from: 2-fluoro-5-hydroxyphenyl, 4-bromo-2-fluorophenyl, 2,4-difluorophenyl, 4-chloro-2-fluorophenyl, 2-fluoro-4-methylphenyl, 2-fluoro-4-methoxyphenyl, 4-bromo-3-hydroxyphenyl, 4-fluoro-3-hydroxyphenyl, 4-chloro-3-hydroxyphenyl, 3-hydroxy-4-methylphenyl, 3-hydroxy-4-methoxyphenyl and 4-cyano-2-fluorophenyl); and salts thereof, processes for their preparation and pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as active ingredient The compounds of formula (I) and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis ##STR1##


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 196603-79-9P

(preparation of 4-anilinoquinazolines for use in the treatment of disease states associated with antiangiogenesis and/or increased vascular permeability)

RN 196603-79-9 USPATFULL

CN Phenol, 5-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]-2-methyl-
(9CI) (CA INDEX NAME)



L24 ANSWER 12 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2001:108033 USPATFULL

TITLE: Chemical compounds

INVENTOR(S): Lohmann, Jean-Jacques Marcel, Merfy, France
Hennequin, Laurent Francois Andre, Champigny sur
Vesles, France

PATENT ASSIGNEE(S): Thomas, Andrew Peter, Congleton, United Kingdom
Zeneca Limited, London, United Kingdom (non-U.S.
corporation)
Zeneca Pharma S.A., Cergy Cedex, France (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6258951	B1	20010710
APPLICATION INFO.:	US 2000-500470		20000209 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-203764, filed on 2 Dec 1998 Continuation of Ser. No. US 1996-768887, filed on 17 Dec 1996, now patented, Pat. No. US 5962458		

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1995-402846	19951218
	EP 1996-402190	19961015

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Kifle, Bruck
LEGAL REPRESENTATIVE: Pillsbury Winthrop LLP
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
LINE COUNT: 5180

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The invention relates to quinazoline derivatives of the formula:
##STR1##

and salts thereof; processes for their preparation and pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient.

The compounds of formula I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 192999-68-1P 192999-70-5P 192999-71-6P
 192999-72-7P 192999-73-8P 192999-74-9P
 192999-75-0P 192999-76-1P 192999-77-2P
 192999-78-3P 192999-79-4P 192999-80-7P
 192999-81-8P 192999-88-5P 192999-89-6P
 192999-90-9P 192999-94-3P 192999-95-4P
 192999-96-5P 192999-98-7P 192999-99-8P
 193000-00-9P 193000-01-0P 193000-02-1P
 193000-03-2P 193000-10-1P 193000-26-9P
 193000-27-0P 193000-39-4P 193000-40-7P
 193000-41-8P 193000-42-9P 193000-43-0P
 193000-44-1P 193000-45-2P 193000-46-3P
 193000-47-4P 193000-59-8P 193000-76-9P
 193000-77-0P 193000-78-1P 193000-79-2P
 193000-80-5P 193000-81-6P 193000-82-7P
 193000-83-8P 193000-84-9P 193000-85-0P
 193000-86-1P 193000-87-2P 193000-88-3P
 193000-89-4P 193000-90-7P 193000-91-8P
 193000-92-9P 193000-93-0P 193000-94-1P
 193000-96-3P 193000-97-4P 193000-98-5P
 193000-99-6P 193001-00-2P 193001-01-3P
 193001-02-4P 193001-03-5P 193001-04-6P
 193001-06-8P 193001-09-1P 193001-14-8P
 193001-16-0P 193001-18-2P 193001-32-0P
 (preparation and antiangiogenic and/or vascular permeability reducing effect
 of quinazoline derivs.)
 RN 192999-68-1 USPATFULL
 CN Phenol, 5-[[6-methoxy-7-(4-pyridinylmethoxy)-4-quinazolinyl]amino]-2-
 methyl-, hydrochloride (5:1) (9CI) (CA INDEX NAME)




●1/5 HCl

RN 192999-70-5 USPATFULL
 CN Phenol, 5-[[6-methoxy-7-(3-pyridinylmethoxy)-4-quinazolinyl]amino]-2-
 methyl- (9CI) (CA INDEX NAME)



RN 192999-71-6 USPATFULL


CN Phenol, 5-[[6-methoxy-7-(2-pyridinylmethoxy)-4-quinazolinyl]amino]-2-methyl-, hydrochloride (4:3) (9CI) (CA INDEX NAME)



●3/4 HCl


RN 192999-72-7 USPATFULL

CN Phenol, 5-[[6-methoxy-7-(4-pyrimidinylmethoxy)-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 192999-73-8 USPATFULL


CN Phenol, 5-[[6-methoxy-7-[(1-methyl-1H-imidazol-2-yl)methoxy]-4-quinazolinyl]amino]-2-methyl-, hydrochloride (10:19) (9CI) (CA INDEX NAME)



●19/10 HCl

RN 192999-74-9 USPATFULL


CN Phenol, 5-[[6-methoxy-7-[(2-methyl-4-thiazolyl)methoxy]-4-quinazolinyl]amino]-2-methyl-, hydrochloride (10:17) (9CI) (CA INDEX NAME)



● 17/10 HCl

RN 192999-75-0 USPATFULL


CN Phenol, 5-[[6-methoxy-7-(3-thienylmethoxy)-4-quinazolinyl]amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 192999-76-1 USPATFULL


CN Acetamide, N-[4-[[[4-[(3-hydroxy-4-methylphenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 192999-77-2 USPATFULL


CN Phenol, 5-[[7-[(3,5-dimethyl-4-isoxazolyl)methoxy]-6-methoxy-4-quinazolinyl]amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 192999-78-3 USPATFULL


CN Phenol, 5-[[6-methoxy-7-[3-(4-pyridinyl)propoxy]-4-quinazolinyl]amino]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 192999-79-4 USPATFULL


CN Phenol, 4-fluoro-5-[[6-methoxy-7-[3-(4-pyridinyl)propoxy]-4-quinazolinyl]amino]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 192999-80-7 USPATFULL


CN Phenol, 4-fluoro-5-[[6-methoxy-7-(4-pyridinylmethoxy)-4-quinazolinyl]amino]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 192999-81-8 USPATFULL


CN Phenol, 4-fluoro-5-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 192999-88-5 USPATFULL

CN Phenol, 4-fluoro-5-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]oxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 192999-89-6 USPATFULL


CN Phenol, 4-fluoro-5-[[6-methoxy-7-[(2-methyl-4-thiazolyl)methoxy]-4-quinazolinyl]amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 192999-90-9 USPATFULL


CN Phenol, 4-fluoro-2-methyl-5-[[7-[(4-pyridinyl)methoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 192999-94-3 USPATFULL


CN Phenol, 4-fluoro-5-[[6-methoxy-7-[(1-methyl-1H-imidazol-2-yl)methoxy]-4-quinazolinyl]amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 192999-95-4 USPATFULL


CN Acetamide, N-[4-[[[4-[(2-fluoro-5-hydroxy-4-methylphenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 192999-96-5 USPATFULL


CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 192999-98-7 USPATFULL

CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-[3-(4-pyridinyl)propoxy]-4-quinazolinyl]amino]-, hydrochloride (10:19) (9CI) (CA INDEX NAME)




●19/10 HCl

RN 192999-99-8 USPATFULL
 CN Phenol, 4-fluoro-5-[[7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino]-2-methyl-, hydrochloride (10:19) (9CI) (CA INDEX NAME)



●19/10 HCl


RN 193000-00-9 USPATFULL
 CN Phenol, 2-chloro-4-fluoro-5-[[7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 193000-01-0 USPATFULL


CN Phenol, 4-fluoro-5-[[6-methoxy-7-[2-(4-pyridinyl)ethoxy]-4-quinazolinyl]amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 193000-02-1 USPATFULL

CN Phenol, 4-fluoro-5-[[6-methoxy-7-(3-thienylmethoxy)-4-quinazolinyl]amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 193000-03-2 USPATFULL
 CN Benzonitrile, 4-[[[4-[(2-fluoro-5-hydroxy-4-methylphenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 193000-10-1 USPATFULL
 CN Phenol, 5-[[[7-[(2-chloro-6-methyl-4-pyridinyl)methoxy]-6-methoxy-4-quinazolinyl]amino]-4-fluoro-2-methyl-, hydrochloride (10:19) (9CI) (CA INDEX NAME)



● 19/10 HCl

RN 193000-26-9 USPATFULL


CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-(4-pyridinylmethoxy)-4-quinazolinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 193000-27-0 USPATFULL

CN Phenol, 5-[[7-[(2-chloro-4-pyridinyl)methoxy]-6-methoxy-4-quinazolinyl]amino]-4-fluoro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 193000-39-4 USPATFULL
CN Phenol, 4-fluoro-2-methyl-5-[[7-(phenylmethoxy)-4-quinazolinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 193000-40-7 USPATFULL
CN Phenol, 2-chloro-4-fluoro-5-[[7-(phenylmethoxy)-4-quinazolinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 193000-41-8 USPATFULL


CN Phenol, 5-[[7-[(3,4-difluorophenyl)methoxy]-6-methoxy-4-quinazolinyl]amino]-4-fluoro-2-methyl-, hydrochloride (10:9) (9CI) (CA INDEX NAME)



● 9/10 HCl

RN 193000-42-9 USPATFULL


CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-[(1-methyl-1H-imidazol-2-yl)methoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 193000-43-0 USPATFULL


CN Phenol, 4-fluoro-2-methyl-5-[[7-[(1-methyl-1H-imidazol-2-yl)methoxy]-4-quinazolinyl]amino]-, hydrochloride (5:9) (9CI) (CA INDEX NAME)



● 9/5 HCl

RN 193000-44-1 USPATFULL


CN Phenol, 4-fluoro-5-[[6-methoxy-7-[2-(1H-1,2,4-triazol-1-yl)ethoxy]-4-quinazolinyl]amino]-2-methyl-, hydrochloride (5:6) (9CI) (CA INDEX NAME)



● 6/5 HCl

RN 193000-45-2 USPATFULL


CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-(3-thienylmethoxy)-4-quinazolinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 193000-46-3 USPATFULL


CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-[2-(4-pyridinyl)ethoxy]-4-quinazolinyl]amino]-, hydrochloride (5:9) (9CI) (CA INDEX NAME)



● 9/5 HCl

RN 193000-47-4 USPATFULL


CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-[(2-methyl-4-thiazolyl)methoxy]-4-quinazolinyl]amino]-, hydrochloride (5:6) (9CI) (CA INDEX NAME)



● 6/5 HCl

RN 193000-59-8 USPATFULL


CN Phenol, 3-[[7-[[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino]-, hydrochloride (10:19) (9CI) (CA INDEX NAME)



●19/10 HCl


RN 193000-76-9 USPATFULL

CN Phenol, 5-[[6-methoxy-7-(4-pyridinylmethoxy)-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-77-0 USPATFULL

CN Phenol, 5-[[6-methoxy-7-(2-pyridinylmethoxy)-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-78-1 USPATFULL

CN Phenol, 5-[[6-methoxy-7-[(1-methyl-1H-imidazol-2-yl)methoxy]-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-79-2 USPATFULL

CN Phenol, 5-[[6-methoxy-7-[(2-methyl-4-thiazolyl)methoxy]-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-80-5 USPATFULL

CN Acetamide, N-[4-[[[4-[(3-hydroxy-4-methylphenyl)amino]-6-methoxy-7-quinazolinyl]oxy)methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 193000-81-6 USPATFULL

CN Phenol, 5-[[6-methoxy-7-[3-(4-pyridinyl)propoxy]-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-82-7 USPATFULL

CN Phenol, 4-fluoro-5-[[6-methoxy-7-[3-(4-pyridinyl)propoxy]-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-83-8 USPATFULL

CN Phenol, 4-fluoro-5-[[6-methoxy-7-(4-pyridinylmethoxy)-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-84-9 USPATFULL

CN Phenol, 4-fluoro-5-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-85-0 USPATFULL

CN Phenol, 4-fluoro-5-[[6-methoxy-7-[(2-methyl-4-thiazolyl)methoxy]-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-86-1 USPATFULL

CN Phenol, 4-fluoro-2-methyl-5-[[7-(4-pyridinylmethoxy)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 193000-87-2 USPATFULL

CN Phenol, 4-fluoro-5-[[6-methoxy-7-[(1-methyl-1H-imidazol-2-yl)methoxy]-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-88-3 USPATFULL

CN Acetamide, N-[4-[[[4-[(2-fluoro-5-hydroxy-4-methylphenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 193000-89-4 USPATFULL

CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]oxy]- (9CI) (CA INDEX NAME)




RN 193000-90-7 USPATFULL

CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-[3-(4-pyridinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 193000-91-8 USPATFULL

CN Phenol, 4-fluoro-5-[[7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-92-9 USPATFULL

CN Phenol, 2-chloro-4-fluoro-5-[[7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 193000-93-0 USPATFULL

CN Phenol, 4-fluoro-5-[[6-methoxy-7-[2-(4-pyridinyl)ethoxy]-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-94-1 USPATFULL

CN Phenol, 4-fluoro-5-[[6-methoxy-7-(3-thienylmethoxy)-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-96-3 USPATFULL

CN Phenol, 5-[[7-[(2-chloro-6-methyl-4-pyridinyl)methoxy]-6-methoxy-4-quinazolinyl]amino]-4-fluoro-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-97-4 USPATFULL

CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-(4-pyridinylmethoxy)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 193000-98-5 USPATFULL


CN Phenol, 5-[[7-[(2-chloro-4-pyridinyl)methoxy]-6-methoxy-4-quinazolinyl]amino]-4-fluoro-2-methyl- (9CI) (CA INDEX NAME)



RN 193000-99-6 USPATFULL


CN Phenol, 5-[[7-[(3,4-difluorophenyl)methoxy]-6-methoxy-4-

quinazolinyl]amino]-4-fluoro-2-methyl- (9CI) (CA INDEX NAME)




RN 193001-00-2 USPATFULL

CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-[(1-methyl-1H-imidazol-2-yl)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 193001-01-3 USPATFULL

CN Phenol, 4-fluoro-2-methyl-5-[[7-[(1-methyl-1H-imidazol-2-yl)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 193001-02-4 USPATFULL

CN Phenol, 4-fluoro-2-methyl-5-[[7-[[2-(1H-1,2,4-triazol-1-yl)ethoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 193001-03-5 USPATFULL


CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-(3-thienylmethoxy)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 193001-04-6 USPATFULL

CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-[2-(4-pyridinyl)ethoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)

quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 193001-06-8 USPATFULL

CN Phenol, 5-[[6-methoxy-7-(3-thienylmethoxy)-4-quinazolinyl]amino]-2-methyl-
(9CI) (CA INDEX NAME)


RN 193001-09-1 USPATFULL

CN Benzonitrile, 4-[[[4-[(2-fluoro-5-hydroxy-4-methylphenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 193001-14-8 USPATFULL

CN Phenol, 4-fluoro-2-methyl-5-[[7-(phenylmethoxy)-4-quinazolinyl]amino] -
(9CI) (CA INDEX NAME)




RN 193001-16-0 USPATFULL

CN Phenol, 2-chloro-4-fluoro-5-[[7-(phenylmethoxy)-4-quinazolinyl]amino] -
(9CI) (CA INDEX NAME)




RN 193001-18-2 USPATFULL

CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-[(2-methyl-4-thiazolyl)methoxy]-4-quinazolinyl]amino] - (9CI) (CA INDEX NAME)



RN 193001-32-0 USPATFULL

CN Phenol, 3-[[7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



L24 ANSWER 13 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2001:18472 USPATFULL

TITLE: Quinazoline derivatives as VEGF inhibitors

INVENTOR(S): Thomas, Andrew Peter, Macclesfield, United Kingdom
 Johnstone, Craig, Macclesfield, United Kingdom
 Hennequin, Laurent Francois Andre, Reims Cedex, France

PATENT ASSIGNEE(S): Zeneca Limited, London, United Kingdom (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6184225	B1	20010206
	WO 9730035		19970821
APPLICATION INFO.:	US 1998-125271		19980813 (9)
	WO 1997-GB365		19970210
			19980813 PCT 371 date
			19980813 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1996-400293	19960213
	EP 1996-401756	19960808
	EP 1996-402764	19961217

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Raymond, Richard L.

ASSISTANT EXAMINER: Schroeder, Ben

LEGAL REPRESENTATIVE: Pillsbury Madison & Sutro LLP Intellectual Property Group

NUMBER OF CLAIMS: 18

EXEMPLARY CLAIM: 1

LINE COUNT: 3619

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to quinazoline derivatives of formula (I) ##STR1##

wherein: Z represents --O--, --NH-- or --S--; m is an integer from 1 to 5; R^{sup.1} represents hydrogen, hydroxy, halogeno, nitro, trifluoromethyl, cyano, C_{sub.1-3} alkyl, C_{sub.1-3} alkoxy, C_{sub.1-3} alkylthio or NR^{sup.5} R^{sup.6} (wherein R^{sup.5} and R^{sup.6}, which may be the same or different, each represents hydrogen or C_{sub.1-3} alkyl);

R.sup.2 represents hydrogen, hydroxy, halogeno, methoxy, amino, or nitro; R.sup.3 represents hydroxy, halogeno, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, C.sub.1-3 alkanoyloxy, trifluoromethyl, cyano, amino or nitro; X.sup.1 represents --O--, --CH.sub.2 --, --S--, --SO--, SO.sub.2 --, --NR.sup.6 --, NR.sup.8 CO--, --CONR.sup.9 --SO.sub.2 NR.sup.10 -- or --NR.sup.11 SO.sub.2 --, (wherein R.sup.7, R.sup.8, R.sup.9, R.sup.10 and R.sup.11 each represents C.sub.1-3 alkyl, C.sub.1-3 alkoxyC.sub.2-3 alkyl); R.sup.4 represents a group which is alkenyl, alkynyl or optionally substituted alkyl, which alkyl group may contain a heteroatom linking group, which alkenyl, alkynyl or alkyl group may carry a terminal optionally substituted 5 or 6 membered saturated carbocyclic or heterocyclic group; and salts thereof, processes for their preparation, pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as active ingredient the compounds of formula (I) and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 192999-96-5P

(preparation of quinazolines as VEGF inhibitors)

RN 192999-96-5 USPATFULL

CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L24 ANSWER 14 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2000:70850 USPATFULL

TITLE: Chemical compounds

INVENTOR(S): Lohmann, Jean-Jacques Marcel, Merfy, France
Hennequin, Laurent Francois Andre, Champigny sur
Vesles, France

PATENT ASSIGNEE(S): Thomas, Andrew Peter, Congleton, United Kingdom
Zeneca Limited, London, United Kingdom (non-U.S.
corporation)
Zeneca Pharma S.A., Cergy Cedex, France (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6071921		20000606
APPLICATION INFO.:	US 1998-203764		19981202 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1996-768887, filed on 17 Dec 1996		

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1995-402846	19951218
	EP 1996-402190	19961015
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Shah, Mukund J.	
ASSISTANT EXAMINER:	Kifle, Bruck	
LEGAL REPRESENTATIVE:	Pillsbury Madison & Sutro, LLP Intellectual Property Group	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
LINE COUNT:	5709	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to quinazoline derivatives of the formula:
 ##STR1## [wherein: Y.sup.1 represents --O--, --S--, --CH.sub.2 --, --SO--, --SO.sub.2 --, --NR.sup.5 CO--, --CONR.sup.6 --, --SO.sub.2 NR.sup.7 --, --NR.sup.8 SO.sub.2 -- or --NR.sup.9 -- (wherein R.sup.5, R.sup.6, R.sup.7, R.sup.8 and R.sup.9 each independently represents hydrogen, alkyl or alkoxyalkyl);

R.sup.1 represents hydrogen, hydroxy, halogeno, nitro, trifluoromethyl, cyano, alkyl, alkoxy, alkylthio, amino or alkylamino.

R.sup.2 represents hydrogen, hydroxy, halogeno, alkyl, alkoxy, trifluoromethyl, cyano, amino or nitro;

m is an integer from 1 to 5;

R.sup.3 represents hydroxy, halogeno, alky, alkoxy, alkanoyloxy, trifluoromethyl, cyano, amino or nitro;

R.sup.4 represents a group which is or which contains an optionally substituted pyridone, phenyl or aromatic heterocyclic group] and salts thereof; processes for their preparation and pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient.

The compounds of formula I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 192999-68-1P 192999-70-5P 192999-71-6P
 192999-72-7P 192999-73-8P 192999-74-9P
 192999-75-0P 192999-76-1P 192999-77-2P
 192999-78-3P 192999-79-4P 192999-80-7P
 192999-81-8P 192999-88-5P 192999-89-6P
 192999-90-9P 192999-94-3P 192999-95-4P
 192999-96-5P 192999-98-7P 192999-99-8P
 193000-00-9P 193000-01-0P 193000-02-1P

193000-03-2P 193000-10-1P 193000-26-9P
193000-27-0P 193000-39-4P 193000-40-7P
193000-41-8P 193000-42-9P 193000-43-0P
193000-44-1P 193000-45-2P 193000-46-3P
193000-47-4P 193000-59-8P 193000-76-9P
193000-77-0P 193000-78-1P 193000-79-2P
193000-80-5P 193000-81-6P 193000-82-7P
193000-83-8P 193000-84-9P 193000-85-0P
193000-86-1P 193000-87-2P 193000-88-3P
193000-89-4P 193000-90-7P 193000-91-8P
193000-92-9P 193000-93-0P 193000-94-1P
193000-96-3P 193000-97-4P 193000-98-5P
193000-99-6P 193001-00-2P 193001-01-3P
193001-02-4P 193001-03-5P 193001-04-6P
193001-06-8P 193001-09-1P 193001-14-8P
193001-16-0P 193001-18-2P 193001-32-0P

(preparation and antiangiogenic and/or vascular permeability reducing effect of quinazoline derivs.)

RN 192999-68-1 USPATFULL


CN Phenol, 5-[[6-methoxy-7-(4-pyridinylmethoxy)-4-quinazolinyl]amino]-2-methyl-, hydrochloride (5:1) (9CI) (CA INDEX NAME)



● 1/5 HCl


RN 192999-70-5 USPATFULL

CN Phenol, 5-[[6-methoxy-7-(3-pyridinylmethoxy)-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 192999-71-6 USPATFULL


CN Phenol, 5-[[6-methoxy-7-(2-pyridinylmethoxy)-4-quinazolinyl]amino]-2-methyl-, hydrochloride (4:3) (9CI) (CA INDEX NAME)



● 3/4 HCl


RN 192999-72-7 USPATFULL

CN Phenol, 5-[[6-methoxy-7-(4-pyrimidinylmethoxy)-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 192999-73-8 USPATFULL


CN Phenol, 5-[[6-methoxy-7-[(1-methyl-1H-imidazol-2-yl)methoxy]-4-quinazolinyl]amino]-2-methyl-, hydrochloride (10:19) (9CI) (CA INDEX NAME)



●19/10 HCl

RN 192999-74-9 USPATFULL


CN Phenol, 5-[[6-methoxy-7-[(2-methyl-4-thiazolyl)methoxy]-4-quinazolinyl]amino]-2-methyl-, hydrochloride (10:17) (9CI) (CA INDEX NAME)



● 17/10 HCl

RN 192999-75-0 USPATFULL


CN Phenol, 5-[[6-methoxy-7-(3-thienylmethoxy)-4-quinazolinyl]amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 192999-76-1 USPATFULL


CN Acetamide, N-[4-[[[4-[(3-hydroxy-4-methylphenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 192999-77-2 USPATFULL


CN Phenol, 5-[[7-[(3,5-dimethyl-4-isoxazolyl)methoxy]-6-methoxy-4-quinazolinyl]amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 192999-78-3 USPATFULL


CN Phenol, 5-[[6-methoxy-7-[3-(4-pyridinyl)propoxy]-4-quinazolinyl]amino]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 192999-79-4 USPATFULL


CN Phenol, 4-fluoro-5-[[[6-methoxy-7-[[3-(4-pyridinyl)propoxy]-4-quinazolinyl]amino]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 192999-80-7 USPATFULL


CN Phenol, 4-fluoro-5-[[[6-methoxy-7-(4-pyridinylmethoxy)-4-quinazolinyl]amino]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 192999-81-8 USPATFULL


CN Phenol, 4-fluoro-5-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 192999-88-5 USPATFULL

CN Phenol, 4-fluoro-5-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]oxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 192999-89-6 USPATFULL


CN Phenol, 4-fluoro-5-[[6-methoxy-7-[(2-methyl-4-thiazolyl)methoxy]-4-quinazolinyl]amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 192999-90-9 USPATFULL


CN Phenol, 4-fluoro-2-methyl-5-[[7-(4-pyridinylmethoxy)-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 192999-94-3 USPATFULL


CN Phenol, 4-fluoro-5-[[6-methoxy-7-[(1-methyl-1H-imidazol-2-yl)methoxy]-4-quinazolinyl]amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 192999-95-4 USPATFULL


CN Acetamide, N-[4-[[[4-[(2-fluoro-5-hydroxy-4-methylphenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 192999-96-5 USPATFULL


CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 192999-98-7 USPATFULL

CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-[3-(4-pyridinyl)propoxy]-4-quinazolinyl]amino]-, hydrochloride (10:19) (9CI) (CA INDEX NAME)




●19/10 HCl

RN 192999-99-8 USPATFULL
 CN Phenol, 4-fluoro-5-[[7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino]-2-methyl-, hydrochloride (10:19) (9CI) (CA INDEX NAME)



●19/10 HCl


RN 193000-00-9 USPATFULL
 CN Phenol, 2-chloro-4-fluoro-5-[[7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 193000-01-0 USPATFULL


CN Phenol, 4-fluoro-5-[[6-methoxy-7-[2-(4-pyridinyl)ethoxy]-4-quinazolinyl]amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 193000-02-1 USPATFULL


CN Phenol, 4-fluoro-5-[[6-methoxy-7-(3-thienylmethoxy)-4-quinazolinyl]amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 193000-03-2 USPATFULL


CN Benzonitrile, 4-[[[4-[(2-fluoro-5-hydroxy-4-methylphenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 193000-10-1 USPATFULL


CN Phenol, 5-[[[7-[(2-chloro-6-methyl-4-pyridinyl)methoxy]-6-methoxy-4-quinazolinyl]amino]-4-fluoro-2-methyl-, hydrochloride (10:19) (9CI) (CA INDEX NAME)



● 19/10 HCl

RN 193000-26-9 USPATFULL


CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-(4-pyridinylmethoxy)-4-quinazolinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 193000-27-0 USPATFULL

CN Phenol, 5-[[7-[(2-chloro-4-pyridinyl)methoxy]-6-methoxy-4-quinazolinyl]amino]-4-fluoro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 193000-39-4 USPATFULL
CN Phenol, 4-fluoro-2-methyl-5-[[7-(phenylmethoxy)-4-quinazolinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 193000-40-7 USPATFULL
CN Phenol, 2-chloro-4-fluoro-5-[[7-(phenylmethoxy)-4-quinazolinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 193000-41-8 USPATFULL


CN Phenol, 5-[[7-[(3,4-difluorophenyl)methoxy]-6-methoxy-4-quinazolinyl]amino]-4-fluoro-2-methyl-, hydrochloride (10:9) (9CI) (CA INDEX NAME)



● 9/10 HCl

RN 193000-42-9 USPATFULL


CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-[(1-methyl-1H-imidazol-2-yl)methoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 193000-43-0 USPATFULL


CN Phenol, 4-fluoro-2-methyl-5-[[7-[(1-methyl-1H-imidazol-2-yl)methoxy]-4-quinazolinyl]amino]-, hydrochloride (5:9) (9CI) (CA INDEX NAME)



● 9/5 HCl

RN 193000-44-1 USPATFULL


CN Phenol, 4-fluoro-5-[[6-methoxy-7-[2-(1H-1,2,4-triazol-1-yl)ethoxy]-4-quinazolinyl]amino]-2-methyl-, hydrochloride (5:6) (9CI) (CA INDEX NAME)



● 6/5 HCl

RN 193000-45-2 USPATFULL


CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-(3-thienylmethoxy)-4-quinazolinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 193000-46-3 USPATFULL


CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-[2-(4-pyridinyl)ethoxy]-4-quinazolinyl]amino]-, hydrochloride (5:9) (9CI) (CA INDEX NAME)



● 9/5 HCl

RN 193000-47-4 USPATFULL


CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-[(2-methyl-4-thiazolyl)methoxy]-4-quinazolinyl]amino]-, hydrochloride (5:6) (9CI) (CA INDEX NAME)



● 6/5 HCl

RN 193000-59-8 USPATFULL


CN Phenol, 3-[[7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino]-, hydrochloride (10:19) (9CI) (CA INDEX NAME)



●19/10 HCl


RN 193000-76-9 USPATFULL

CN Phenol, 5-[[6-methoxy-7-(4-pyridinylmethoxy)-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-77-0 USPATFULL

CN Phenol, 5-[[6-methoxy-7-(2-pyridinylmethoxy)-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-78-1 USPATFULL

CN Phenol, 5-[[6-methoxy-7-[(1-methyl-1H-imidazol-2-yl)methoxy]-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-79-2 USPATFULL

CN Phenol, 5-[[6-methoxy-7-[(2-methyl-4-thiazolyl)methoxy]-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-80-5 USPATFULL

CN Acetamide, N-[4-[[[4-[(3-hydroxy-4-methylphenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 193000-81-6 USPATFULL

CN Phenol, 5-[[6-methoxy-7-[3-(4-pyridinyl)propoxy]-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-82-7 USPATFULL

CN Phenol, 4-fluoro-5-[[6-methoxy-7-[3-(4-pyridinyl)propoxy]-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-83-8 USPATFULL

CN Phenol, 4-fluoro-5-[[6-methoxy-7-(4-pyridinylmethoxy)-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-84-9 USPATFULL

CN Phenol, 4-fluoro-5-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-85-0 USPATFULL

CN Phenol, 4-fluoro-5-[[6-methoxy-7-[(2-methyl-4-thiazolyl)methoxy]-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-86-1 USPATFULL

CN Phenol, 4-fluoro-2-methyl-5-[[7-(4-pyridinylmethoxy)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 193000-87-2 USPATFULL

CN Phenol, 4-fluoro-5-[[6-methoxy-7-[(1-methyl-1H-imidazol-2-yl)methoxy]-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-88-3 USPATFULL

CN Acetamide, N-[4-[[[4-[(2-fluoro-5-hydroxy-4-methylphenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 193000-89-4 USPATFULL

CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]oxy]- (9CI) (CA INDEX NAME)




RN 193000-90-7 USPTAFULL

CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-[3-(4-pyridinyl)propoxy]-4-quinazoliny]amino]- (9CI) (CA INDEX NAME)




RN 193000-91-8 USPTAFULL

CN Phenol, 4-fluoro-5-[[7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazoliny]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-92-9 USPTAFULL

CN Phenol, 2-chloro-4-fluoro-5-[[7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazoliny]amino]- (9CI) (CA INDEX NAME)




RN 193000-93-0 USPATFULL

CN Phenol, 4-fluoro-5-[[6-methoxy-7-[2-(4-pyridinyl)ethoxy]-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-94-1 USPATFULL

CN Phenol, 4-fluoro-5-[[6-methoxy-7-(3-thienylmethoxy)-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-96-3 USPATFULL

CN Phenol, 5-[[7-[(2-chloro-6-methyl-4-pyridinyl)methoxy]-6-methoxy-4-quinazolinyl]amino]-4-fluoro-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-97-4 USPATFULL

CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-(4-pyridinylmethoxy)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 193000-98-5 USPATFULL


CN Phenol, 5-[[7-[(2-chloro-4-pyridinyl)methoxy]-6-methoxy-4-quinazolinyl]amino]-4-fluoro-2-methyl- (9CI) (CA INDEX NAME)



RN 193000-99-6 USPATFULL


CN Phenol, 5-[[7-[(3,4-difluorophenyl)methoxy]-6-methoxy-4-

quinazolinyl]amino]-4-fluoro-2-methyl- (9CI) (CA INDEX NAME)




RN 193001-00-2 USPATFULL

CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-[(1-methyl-1H-imidazol-2-yl)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 193001-01-3 USPATFULL

CN Phenol, 4-fluoro-2-methyl-5-[[7-[(1-methyl-1H-imidazol-2-yl)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 193001-02-4 USPATFULL

CN Phenol, 4-fluoro-2-methyl-5-[[7-[2-(1H-1,2,4-triazol-1-yl)ethoxy]-4-quinazolinyl]amino] - (9CI) (CA INDEX NAME)



RN 193001-03-5 USPATFULL


CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-(3-thienylmethoxy)-4-quinazolinyl]amino] - (9CI) (CA INDEX NAME)




RN 193001-04-6 USPATFULL

CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-[2-(4-pyridinyl)ethoxy]-4-quinazolinyl]amino] - (9CI) (CA INDEX NAME)

quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 193001-06-8 USPATFULL

CN Phenol, 5-[[6-methoxy-7-(3-thienylmethoxy)-4-quinazolinyl]amino]-2-methyl-
(9CI) (CA INDEX NAME)


RN 193001-09-1 USPATFULL

CN Benzonitrile, 4-[[[4-[(2-fluoro-5-hydroxy-4-methylphenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 193001-14-8 USPATFULL

CN Phenol, 4-fluoro-2-methyl-5-[[7-(phenylmethoxy)-4-quinazolinyl]amino] -
(9CI) (CA INDEX NAME)




RN 193001-16-0 USPATFULL

CN Phenol, 2-chloro-4-fluoro-5-[[7-(phenylmethoxy)-4-quinazolinyl]amino] -
(9CI) (CA INDEX NAME)




RN 193001-18-2 USPATFULL

CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-[(2-methyl-4-thiazolyl)methoxy]-4-quinazolinyl]amino] - (9CI) (CA INDEX NAME)



RN 193001-32-0 USPATFULL

CN Phenol, 3-[[7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)



L24 ANSWER 15 OF 15 USPATFULL on STN

ACCESSION NUMBER: 1999:121360 USPATFULL

TITLE: Substituted quinazolines

INVENTOR(S): Lohmann, Jean-Jacques Marcel, Merfy, France
Hennequin, Laurent Francois Andre, Champigny sur
Vesles, FrancePATENT ASSIGNEE(S): Thomas, Andrew Peter, Congleton, United Kingdom
Zeneca Limited, London, United Kingdom (non-U.S.
corporation)
Zeneca Pharma S.A., Cergy Cedex, France (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5962458		19991005
APPLICATION INFO.:	US 1996-768887		19961217 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1995-402846	19951218
	EP 1996-402190	19961015

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Shah, Mukund J.
 ASSISTANT EXAMINER: Kifle, Bruck
 LEGAL REPRESENTATIVE: Pillsbury Madison & Sutro
 NUMBER OF CLAIMS: 14
 EXEMPLARY CLAIM: 1
 LINE COUNT: 5497

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to quinazoline derivatives of the formula:
 ##STR1## [wherein: Y.sup.1 represents --O--, --S--, --CH.sub.2 --,
 --SO--, --SO.sub.2 --, --NR.sup.5 CO--, --CONR.sup.6 -, --SO.sub.2
 NR.sup.7 -, --NR.sup.8 SO.sub.2 -- or --NR.sup.9 - (wherein R.sup.5,
 R.sup.6, R.sup.7, R.sup.8 and R.sup.9 each independently represents
 hydrogen, alkyl or alkoxyalkyl);

R.sup.1 represents hydrogen, hydroxy, halogeno, nitro, trifluoromethyl,
 cyano, alkyl, alkoxy, alkylthio, amino or alkylamino.

R.sup.2 represents hydrogen, hydroxy, halogeno, alkyl, alkoxy, trifluoromethyl, cyano, amino or nitro;

m is an integer from 1 to 5;

R.sup.3 represents hydroxy, halogeno, alkyl, alkoxy, alkanoyloxy, trifluoromethyl, cyano, amino or nitro;

R.sup.4 represents a group which is or which contains an optionally substituted pyridone, phenyl or aromatic heterocyclic group] and salts thereof; processes for their preparation and pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient. The compounds of formula I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 192999-68-1P 192999-70-5P 192999-71-6P

192999-72-7P 192999-73-8P 192999-74-9P

192999-75-0P 192999-76-1P 192999-77-2P

192999-78-3P 192999-79-4P 192999-80-7P

192999-81-8P 192999-88-5P 192999-89-6P

192999-90-9P 192999-94-3P 192999-95-4P

192999-96-5P 192999-98-7P 192999-99-8P

193000-00-9P 193000-01-0P 193000-02-1P

193000-03-2P 193000-10-1P 193000-26-9P

193000-27-0P 193000-39-4P 193000-40-7P

193000-41-8P 193000-42-9P 193000-43-0P

193000-44-1P 193000-45-2P 193000-46-3P

193000-47-4P 193000-59-8P 193000-76-9P

193000-77-0P 193000-78-1P 193000-79-2P

193000-80-5P 193000-81-6P 193000-82-7P

193000-83-8P 193000-84-9P 193000-85-0P

193000-86-1P 193000-87-2P 193000-88-3P

193000-89-4P 193000-90-7P 193000-91-8P

193000-92-9P 193000-93-0P 193000-94-1P

193000-96-3P 193000-97-4P 193000-98-5P

193000-99-6P 193001-00-2P 193001-01-3P

193001-02-4P 193001-03-5P 193001-04-6P


193001-06-8P 193001-09-1P 193001-14-8P

193001-16-0P 193001-18-2P 193001-32-0P

(preparation and antiangiogenic and/or vascular permeability reducing effect of quinazoline derivs.)

RN 192999-68-1 USPATFULL


CN Phenol, 5-[[6-methoxy-7-(4-pyridinylmethoxy)-4-quinazolinyl]amino]-2-methyl-, hydrochloride (5:1) (9CI) (CA INDEX NAME)



● 1/5 HCl


RN 192999-70-5 USPATFULL

CN Phenol, 5-[[6-methoxy-7-(3-pyridinylmethoxy)-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 192999-71-6 USPATFULL


CN Phenol, 5-[[6-methoxy-7-(2-pyridinylmethoxy)-4-quinazolinyl]amino]-2-methyl-, hydrochloride (4:3) (9CI) (CA INDEX NAME)



● 3/4 HCl


RN 192999-72-7 USPATFULL

CN Phenol, 5-[[6-methoxy-7-(4-pyrimidinylmethoxy)-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 192999-73-8 USPATFULL


CN Phenol, 5-[[6-methoxy-7-[(1-methyl-1H-imidazol-2-yl)methoxy]-4-quinazolinyl]amino]-2-methyl-, hydrochloride (10:19) (9CI) (CA INDEX NAME)



●19/10 HCl

RN 192999-74-9 USPATFULL


CN Phenol, 5-[[6-methoxy-7-[(2-methyl-4-thiazolyl)methoxy]-4-quinazolinyl]amino]-2-methyl-, hydrochloride (10:17) (9CI) (CA INDEX NAME)



●17/10 HCl

RN 192999-75-0 USPATFULL


CN Phenol, 5-[[6-methoxy-7-(3-thienylmethoxy)-4-quinazolinyl]amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 192999-76-1 USPATFULL


CN Acetamide, N-[4-[[[4-[(3-hydroxy-4-methylphenyl)amino]-6-methoxy-7-quinazolinyl]oxy)methyl]-2-thiazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 192999-77-2 USPATFULL


CN Phenol, 5-[[7-[(3,5-dimethyl-4-isoxazolyl)methoxy]-6-methoxy-4-quinazolinyl]amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 192999-78-3 USPATFULL


CN Phenol, 5-[[6-methoxy-7-[3-(4-pyridinyl)propoxy]-4-quinazolinyl]amino]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 192999-79-4 USPATFULL


CN Phenol, 4-fluoro-5-[[6-methoxy-7-[3-(4-pyridinyl)propoxy]-4-quinazolinyl]amino]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 192999-80-7 USPATFULL


CN Phenol, 4-fluoro-5-[[6-methoxy-7-(4-pyridinylmethoxy)-4-quinazolinyl]amino]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 192999-81-8 USPATFULL


CN Phenol, 4-fluoro-5-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 192999-88-5 USPATFULL

CN Phenol, 4-fluoro-5-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]oxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 192999-89-6 USPATFULL


CN Phenol, 4-fluoro-5-[[6-methoxy-7-[(2-methyl-4-thiazolyl)methoxy]-4-quinazolinyl]amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 192999-90-9 USPATFULL


CN Phenol, 4-fluoro-2-methyl-5-[[7-(4-pyridinylmethoxy)-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 192999-94-3 USPATFULL

CN Phenol, 4-fluoro-5-[[6-methoxy-7-[(1-methyl-1H-imidazol-2-yl)methoxy]-4-quinazolinyl]amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 192999-95-4 USPATFULL
 CN Acetamide, N-[4-[[[4-[(2-fluoro-5-hydroxy-4-methylphenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 192999-96-5 USPATFULL
 CN Phenol, 2-chloro-4-fluoro-5-[[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 192999-98-7 USPATFULL


CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-[3-(4-pyridinyl)propoxy]-4-quinazolinyl]amino]-, hydrochloride (10:19) (9CI) (CA INDEX NAME)



● 19/10 HCl

RN 192999-99-8 USPATFULL


CN Phenol, 4-fluoro-5-[[7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino]-2-methyl-, hydrochloride (10:19) (9CI) (CA INDEX NAME)



●19/10 HCl

RN 193000-00-9 USPATFULL


CN Phenol, 2-chloro-4-fluoro-5-[[7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 193000-01-0 USPATFULL


CN Phenol, 4-fluoro-5-[[6-methoxy-7-[2-(4-pyridinyl)ethoxy]-4-quinazolinyl]amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 193000-02-1 USPATFULL


CN Phenol, 4-fluoro-5-[[[6-methoxy-7-(3-thienylmethoxy)-4-quinazolinyl]amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 193000-03-2 USPATFULL


CN Benzonitrile, 4-[[[4-[(2-fluoro-5-hydroxy-4-methylphenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 193000-10-1 USPATFULL


CN Phenol, 5-[[7-[(2-chloro-6-methyl-4-pyridinyl)methoxy]-6-methoxy-4-quinazolinyl]amino]-4-fluoro-2-methyl-, hydrochloride (10:19) (9CI) (CA INDEX NAME)



● 19/10 HCl

RN 193000-26-9 USPATFULL


CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-(4-pyridinylmethoxy)-4-quinazolinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 193000-27-0 USPATFULL


CN Phenol, 5-[[7-[(2-chloro-4-pyridinyl)methoxy]-6-methoxy-4-quinazolinyl]amino]-4-fluoro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 193000-39-4 USPATFULL


CN Phenol, 4-fluoro-2-methyl-5-[[7-(phenylmethoxy)-4-quinazolinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 193000-40-7 USPATFULL


CN Phenol, 2-chloro-4-fluoro-5-[[7-(phenylmethoxy)-4-quinazolinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 193000-41-8 USPATFULL


CN Phenol, 5-[[7-[(3,4-difluorophenyl)methoxy]-6-methoxy-4-quinazolinyl]amino]-4-fluoro-2-methyl-, hydrochloride (10:9) (9CI) (CA INDEX NAME)



●9/10 HCl

RN 193000-42-9 USPATFULL


CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-[(1-methyl-1H-imidazol-2-yl)methoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 193000-43-0 USPATFULL


CN Phenol, 4-fluoro-2-methyl-5-[[7-[(1-methyl-1H-imidazol-2-yl)methoxy]-4-quinazolinyl]amino]-, hydrochloride (5:9) (9CI) (CA INDEX NAME)



● 9/5 HCl

RN 193000-44-1 USPATFULL


CN Phenol, 4-fluoro-5-[[6-methoxy-7-[2-(1H-1,2,4-triazol-1-yl)ethoxy]-4-quinazolinyl]amino]-2-methyl-, hydrochloride (5:6) (9CI) (CA INDEX NAME)



● 6/5 HCl

RN 193000-45-2 USPATFULL


CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-(3-thienylmethoxy)-4-quinazolinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 193000-46-3 USPATFULL


CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-[2-(4-pyridinyl)ethoxy]-4-quinazolinyl]amino]-, hydrochloride (5:9) (9CI) (CA INDEX NAME)



● 9/5 HCl

RN 193000-47-4 USPATFULL


CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-[(2-methyl-4-thiazolyl)methoxy]-4-quinazolinyl]amino]-, hydrochloride (5:6) (9CI) (CA INDEX NAME)



● 6/5 HCl

RN 193000-59-8 USPATFULL


CN Phenol, 3-[[7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino]-, hydrochloride (10:19) (9CI) (CA INDEX NAME)



● 19/10 HCl


RN 193000-76-9 USPATFULL

CN Phenol, 5-[[6-methoxy-7-(4-pyridinylmethoxy)-4-quinazolinyl]amino]-2-methyl-, (9CI) (CA INDEX NAME)




RN 193000-77-0 USPATFULL

CN Phenol, 5-[[6-methoxy-7-(2-pyridinylmethoxy)-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-78-1 USPATFULL

CN Phenol, 5-[[6-methoxy-7-[(1-methyl-1H-imidazol-2-yl)methoxy]-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-79-2 USPATFULL

CN Phenol, 5-[[6-methoxy-7-[(2-methyl-4-thiazolyl)methoxy]-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-80-5 USPATFULL

CN Acetamide, N-[4-[[[4-[(3-hydroxy-4-methylphenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 193000-81-6 USPATFULL

CN Phenol, 5-[[[6-methoxy-7-[3-(4-pyridinyl)propoxy]-4-quinazolinyl]amino]-2-methyl]- (9CI) (CA INDEX NAME)




RN 193000-82-7 USPATFULL

CN Phenol, 4-fluoro-5-[[[6-methoxy-7-[3-(4-pyridinyl)propoxy]-4-quinazolinyl]amino]-2-methyl]- (9CI) (CA INDEX NAME)




RN 193000-83-8 USPATFULL

CN Phenol, 4-fluoro-5-[[6-methoxy-7-(4-pyridinylmethoxy)-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-84-9 USPATFULL

CN Phenol, 4-fluoro-5-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-85-0 USPATFULL

CN Phenol, 4-fluoro-5-[[6-methoxy-7-[(2-methyl-4-thiazolyl)methoxy]-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-86-1 USPATFULL

CN Phenol, 4-fluoro-2-methyl-5-[[7-(4-pyridinylmethoxy)-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)




RN 193000-87-2 USPATFULL

CN Phenol, 4-fluoro-5-[[6-methoxy-7-[(1-methyl-1H-imidazol-2-yl)methoxy]-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-88-3 USPATFULL

CN Acetamide, N-[4-[[[4-[(2-fluoro-5-hydroxy-4-methylphenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 193000-89-4 USPATFULL

CN Phenol, 2-chloro-4-fluoro-5-[[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]oxy]- (9CI) (CA INDEX NAME)




RN 193000-90-7 USPATFULL

CN Phenol, 2-chloro-4-fluoro-5-[[[6-methoxy-7-[3-(4-pyridinyl)propoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 193000-91-8 USPATFULL

CN Phenol, 4-fluoro-5-[[7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-92-9 USPATFULL

CN Phenol, 2-chloro-4-fluoro-5-[[7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 193000-93-0 USPATFULL

CN Phenol, 4-fluoro-5-[[6-methoxy-7-[2-(4-pyridinyl)ethoxy]-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-94-1 USPATFULL

CN Phenol, 4-fluoro-5-[[6-methoxy-7-(3-thienylmethoxy)-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-96-3 USPATFULL

CN Phenol, 5-[[7-[(2-chloro-6-methyl-4-pyridinyl)methoxy]-6-methoxy-4-quinazolinyl]amino]-4-fluoro-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-97-4 USPATFULL

CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-(4-pyridinylmethoxy)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 193000-98-5 USPATFULL

CN Phenol, 5-[[7-[(2-chloro-4-pyridinyl)methoxy]-6-methoxy-4-quinazolinyl]amino]-4-fluoro-2-methyl- (9CI) (CA INDEX NAME)




RN 193000-99-6 USPATFULL

CN Phenol, 5-[[7-[(3,4-difluorophenyl)methoxy]-6-methoxy-4-quinazolinyl]amino]-4-fluoro-2-methyl- (9CI) (CA INDEX NAME)




RN 193001-00-2 USPATFULL

CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-[(1-methyl-1H-imidazol-2-yl)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 193001-01-3 USPATFULL

CN Phenol, 4-fluoro-2-methyl-5-[[7-[(1-methyl-1H-imidazol-2-yl)methoxy]-4-quinazolinyl]amino] - (9CI) (CA INDEX NAME)




RN 193001-02-4 USPATFULL

CN Phenol, 4-fluoro-2-methyl-5-[[7-[2-(1H-1,2,4-triazol-1-yl)ethoxy]-4-quinazolinyl]amino] - (9CI) (CA INDEX NAME)




RN 193001-03-5 USPATFULL

CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-(3-thienylmethoxy)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 193001-04-6 USPATFULL

CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-[2-(4-pyridinyl)ethoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 193001-06-8 USPATFULL

CN Phenol, 5-[[6-methoxy-7-(3-thienylmethoxy)-4-quinazolinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 193001-09-1 USPATFULL

CN Benzonitrile, 4-[[[4-[(2-fluoro-5-hydroxy-4-methylphenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 193001-14-8 USPATFULL

CN Phenol, 4-fluoro-2-methyl-5-[[[7-(phenylmethoxy)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 193001-16-0 USPATFULL

CN Phenol, 2-chloro-4-fluoro-5-[[[7-(phenylmethoxy)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 193001-18-2 USPATFULL

CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-[(2-methyl-4-thiazolyl)methoxy]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 193001-32-0 USPATFULL

CN Phenol, 3-[[7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



AUTHOR Search in CAPLUS, usPatfull, usPat2, Toxcenter

Truong 10_088854

10/18/2005

=> file caplus

FILE 'CAPLUS' ENTERED AT 14:54:59 ON 18 OCT 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Oct 2005 VOL 143 ISS 17

FILE LAST UPDATED: 17 Oct 2005 (20051017/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> d que L18

L16 296 SEA FILE=CAPLUS ABB=ON PLU=ON KEEN N?/AU

L17 66 SEA FILE=CAPLUS ABB=ON PLU=ON MORTLOCK A?/AU

L18 8 SEA FILE=CAPLUS ABB=ON PLU=ON L16 AND L17

=> file uspatall toxcenter

FILE 'USPATFULL' ENTERED AT 14:55:26 ON 18 OCT 2005

CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 14:55:26 ON 18 OCT 2005

CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'TOXCENTER' ENTERED AT 14:55:26 ON 18 OCT 2005

COPYRIGHT (C) 2005 ACS

=> d que L27

L25 60 SEA KEEN N?/AU

L26 25 SEA MORTLOCK A?/AU

L27 8 SEA L25 AND L26

=> dup rem L18 L27

FILE 'CAPLUS' ENTERED AT 14:55:50 ON 18 OCT 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'TOXCENTER' ENTERED AT 14:55:50 ON 18 OCT 2005

COPYRIGHT (C) 2005 ACS

PROCESSING COMPLETED FOR L18

PROCESSING COMPLETED FOR L27

L28 8 DUP REM L18 L27 (8 DUPLICATES REMOVED)

ANSWERS '1-8' FROM FILE CAPLUS

=> d ibib abs hitind L28 1-8

L28 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2005:955257 CAPLUS

TITLE: Progress in the development of selective inhibitors of Aurora Kinases

AUTHOR(S): **Mortlock, Andrew A.; Keen, Nicholas J.;** Jung, Frederic H.; Heron, Nicola M.; Foote, Kevin M.; Wilkinson, Robert W.; Green, Stephen

CORPORATE SOURCE: AstraZeneca, Macclesfield, SK10 4TG, UK

SOURCE: Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates) (2005), 5(8), 807-821

CODEN: CTMCCL; ISSN: 1568-0266

PUBLISHER: Bentham Science Publishers Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Errors in the mitotic process are thought to be one of the principal sources of the genetic instability that hallmarks cancer. Unsurprisingly, many of the proteins that regulate mitosis are aberrantly expressed in tumor cells when compared to their normal counterparts. These may represent a good source of targets for the development of novel anticancer agents. The Aurora kinases represent one such family of mitotic regulators. In recent years there has been intense interest in both understanding the role of the Aurora kinases in cell cycle regulation and also in developing small mol. inhibitors as potential novel anti-cancer drugs. With several companies now starting to take Aurora kinase inhibitors into clin. development, the time is right to review the medicinal chemical contribution to developing the field, in particular to review the increasingly broad range of small mol. inhibitors with activity against this kinase family.

CC 7 (Enzymes)

REFERENCE COUNT: 141 THERE ARE 141 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 2005:955256 CAPLUS

TITLE: Progress in the development of selective inhibitors of Aurora kinases. [Erratum to document cited in CA142:475149]

AUTHOR(S): **Mortlock, Andrew; Keen, Nicholas J.** ; Jung, Frederic H.; Heron, Nicola M.; Foote, Kevin M.; Wilkinson, Robert; Green, Stephen

CORPORATE SOURCE: Cancer and Infection Research Area (CIRA), AstraZeneca, Macclesfield, SK10 4TG, UK

SOURCE: Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates) (2005), 5(8), 805

CODEN: CTMCCL; ISSN: 1568-0266

PUBLISHER: Bentham Science Publishers Ltd.

DOCUMENT TYPE: Journal; General Review; Errata

LANGUAGE: English

AB A review. An erratum.

CC 1-0 (Pharmacology)

IT INDEXING IN PROGRESS

L28 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 3

ACCESSION NUMBER: 2005:318734 CAPLUS

DOCUMENT NUMBER: 142:475149
TITLE: Progress in the development of selective inhibitors of Aurora kinases
AUTHOR(S): **Mortlock, Andrew; Keen, Nicholas J.**
; Jung, Frederic H.; Heron, Nicola M.; Foote, Kevin M.; Wilkinson, Robert; Green, Stephen
CORPORATE SOURCE: Cancer and Infection Research Area (CIRA), AstraZeneca, Macclesfield, SK10 4TG, UK
SOURCE: Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates) (2005), 5(2), 199-213
CODEN: CTMCCL; ISSN: 1568-0266
PUBLISHER: Bentham Science Publishers Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review. Errors in the mitotic process are thought to be one of the principal sources of the genetic instability that hallmarks cancer. Unsurprisingly, many of the proteins that regulate mitosis are aberrantly expressed in tumor cells when compared to their normal counterparts. These may represent a good source of targets for the development of novel anti-cancer agents. The Aurora kinases represent one such family of mitotic regulators. In recent years there was intense interest in both understanding the role of the Aurora kinases in cell cycle regulation and also in developing small mol. inhibitors as potential novel anti-cancer drugs. With several companies now starting to take Aurora kinase inhibitors into clin. development, the time is right to review the medicinal chemical contribution to developing the field, in particular to review the increasingly broad range of small mol. inhibitors with activity against this kinase family.

CC 1-0 (Pharmacology)

REFERENCE COUNT: 71 THERE ARE 71 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 4

ACCESSION NUMBER: 2003:339130 CAPLUS
DOCUMENT NUMBER: 139:143528
TITLE: Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores
AUTHOR(S): Ditchfield, Claire; Johnson, Victoria L.; Tighe, Anthony; Ellston, Rebecca; Haworth, Carolyn; Johnson, Trevor; **Mortlock, Andrew; Keen, Nicholas**; Taylor, Stephen S.
CORPORATE SOURCE: School of Biological Sciences, University of Manchester, Manchester, M13 9PT, UK
SOURCE: Journal of Cell Biology (2003), 161(2), 267-280
CODEN: JCLBA3; ISSN: 0021-9525
PUBLISHER: Rockefeller University Press
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The Aurora/Ipl1 family of protein kinases plays multiple roles in mitosis and cytokinesis. Here, we describe ZM447439, a novel selective Aurora kinase inhibitor. Cells treated with ZM447439 progress through interphase, enter mitosis normally, and assemble bipolar spindles. However, chromosome alignment, segregation, and cytokinesis all fail. Despite the presence of maloriented chromosomes, ZM447439-treated cells exit mitosis with normal kinetics, indicating that the spindle checkpoint is compromised. Indeed, ZM447439 prevents mitotic arrest after exposure to paclitaxel. RNA interference expts. suggest that these phenotypes are due to inhibition of Aurora B, not Aurora A or some other kinase. In the absence of Aurora B function, kinetochore localization of the spindle

checkpoint components BubR1, Mad2, and Cenp-E is diminished. Furthermore, inhibition of Aurora B kinase activity prevents the rebinding of BubR1 to metaphase kinetochores after a reduction in centromeric tension. Aurora B kinase activity is also required for phosphorylation of BubR1 on entry into mitosis. Finally, we show that BubR1 is not only required for spindle checkpoint function, but is also required for chromosome alignment. Together, these results suggest that by targeting checkpoint proteins to kinetochores, Aurora B couples chromosome alignment with anaphase onset.

CC 1-6 (Pharmacology)

REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 5

ACCESSION NUMBER: 2001:228867 CAPLUS

DOCUMENT NUMBER: 134:266318

TITLE: Preparation of quinazolines as aurora 2 kinase inhibitors

INVENTOR(S): Mortlock, Andrew Austen; Keen, Nicholas John

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 208 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001021597	A1	20010329	WO 2000-GB3593	20000919
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2384296	AA	20010329	CA 2000-2384296	20000919
BR 2000014137	A	20020521	BR 2000-14137	20000919
TR 200200717	T2	20020621	TR 2002-200200717	20000919
EP 1218355	A1	20020703	EP 2000-960850	20000919
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003509500	T2	20030311	JP 2001-524976	20000919
EE 200200118	A	20030415	EE 2002-118	20000919
AU 762697	B2	20030703	AU 2000-73019	20000919
BG 106526	A	20021031	BG 2002-106526	20020318
ZA 2002002232	A	20030619	ZA 2002-2232	20020319
NO 2002001400	A	20020506	NO 2002-1400	20020320
PRIORITY APPLN. INFO.:			GB 1999-22171	A 19990921
			WO 2000-GB3593	W 20000919
OTHER SOURCE(S):	MARPAT	134:266318		
GI				



I



II

AB Title compds. (I) [wherein X = O, S, SO, SO₂, NH, or NR₆; R₆ = H or alkyl; R₅ = (un)substituted 6-membered aromatic ring containing at least one N; R₁-R₄

=

independently halo, CN, NO₂, alkylsulfanyl, N(OH)R₇, or R₉X₁; R₇ = H or alkyl; X₁ = a direct bond, O, CH₂, OC(O), CO, S, SO, SO₂, or (un)substituted NHCO, CONH, SO₂NH, NHSO₂, or NH; R₉ = H or (un)substituted hydrocarbonyl, heterocyclyl, or alkoxy; and at least one of R₂ or R₃ is other than H; or a salt, ester, amide, or prodrug thereof] were prepared as aurora 2 kinase inhibitors for the treatment of proliferative diseases, such as cancer. For example, 2-(N-benzoylamino)-5-aminopyrimidine and 4-chloro-6,7-dimethoxyquinazoline were coupled in i-PrOH to yield II (58%). The latter inhibited the serine/threonine kinase activity of aurora 2 kinase by 50% at a concentration of 0.00785 μM. In addition, II gave 50% inhibition of MCF-7 cell proliferation at 1.7 μM and reduced BrdU incorporation into cellular DNA by 50% at 1.92-2.848 μM.

IC ICM C07D239-94

ICS C07D401-12; C07D403-12; A61K031-517; A61P035-00

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 6

ACCESSION NUMBER: 2001:228866 CAPLUS

DOCUMENT NUMBER: 134:266317

TITLE: Preparation of quinazolines as aurora 2 kinase inhibitors

INVENTOR(S): Mortlock, Andrew Austen; Keen, Nicholas John; Jung, Frederic Henri; Brewster, Andrew George

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 306 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001021596	A1	20010329	WO 2000-GB3580	20000918
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,				


YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
 CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2384291	AA	20010329	CA 2000-2384291	20000918
BR 2000014116	A	20020521	BR 2000-14116	20000918
EP 1218354	A1	20020703	EP 2000-960840	20000918
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003509499	T2	20030311	JP 2001-524975	20000918
EE 200200119	A	20030415	EE 2002-119	20000918
BG 106492	A	20030131	BG 2002-106492	20020307
ZA 2002002234	A	20030619	ZA 2002-2234	20020319
NO 2002001399	A	20020430	NO 2002-1399	20020320
PRIORITY APPLN. INFO.:			GB 1999-22154	A 19990921
			GB 1999-22170	A 19990921
			WO 2000-GB3580	W 20000918

OTHER SOURCE(S): MARPAT 134:266317
 GI



I



II

AB Title compds. (I) [wherein X = O, S, SO, SO₂, NH, or NR₁₂; R₁₂ = H or alkyl; R₁-R₄ = independently halo, CN, NO₂, alkylsulfanyl, N(OH)R₁₃, or R₁₅X₁; R₁₃ = H or alkyl; X₁ = a direct bond, O, CH₂, OC(O), CO, CO₂, S, SO, SO₂, or (un)substituted NHCO, CONH, SO₂NH, NHSO₂, or NH; R₁₅ = H or (un)substituted hydrocarbyl, heterocyclyl, or alkoxy; R₅ = NHCO₂R₉, NHCOR₉, NHSO₂R₉, COR₉, CO₂R₉, SOR₉, SO₂OR₉, CONR₁₀R₁₁, SONR₁₀R₁₁, or SO₂NR₁₀R₁₁; R₉-R₁₁ = independently H or (un)substituted hydrocarbyl or heterocyclyl; or R₁₀ and R₁₁ together with the N to which they are attached = (un)substituted heterocyclyl; R₆ = H or (un)substituted hydrocarbyl or heterocyclyl; R₇ and R₈ = independently H, halo, alkyl, (di)alkoxy(methyl), alkanoyl, CF₃, CN, NHY₂, alkenyl, alkynyl, or (un)substituted Ph, PhCH₂, or heterocyclyl; or a salt, ester, or amide

thereof] were prepared as aurora 2 kinase inhibitors for the treatment of proliferative diseases, such as cancer. For example, a 7-step sequence involving (1) alkylation of morpholine with 1-bromo-3-chloropropane (49%), (2) addition of Et vanillate to yield Et 3-methoxy-4-(3-morpholinopropoxy)benzoate (100%), (3) nitration (86%), (4) reduction to the amine using 10% Pd/C (100%), (5) cycloaddn. with formamide to form the quinazoline(68%), (6) chlorination to give 4-chloro-6-methoxy-7-(3-morpholinopropoxy)quinazoline (60%), and (7) amination with N-benzoyl-4-aminoaniline (58%) yielded II. The latter inhibited the serine/threonine kinase activity of aurora 2 kinase by 50% at a concentration

of

0.0193 μ M. In addition, II gave 50% inhibition of MCF-7 cell proliferation at 1.06 μ M and reduced BrdU incorporation into cellular DNA by 50% at 0.159-0.209 μ M.

IC ICM C07D239-94

ICS A61K031-517; A61P035-00

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 7

ACCESSION NUMBER: 2001:228865 CAPLUS

DOCUMENT NUMBER: 134:266316

TITLE: Preparation of quinazoline derivatives, method of preparation and use in inhibiting aurora 2 kinase

INVENTOR(S): Mortlock, Andrew Austen; Keen, Nicholas John

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 83 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001021595	A1	20010329	WO 2000-GB3562	20000918
W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
CA 2384284	AA	20010329	CA 2000-2384284	20000918
BR 2000014136	A	20020521	BR 2000-14136	20000918
EP 1218357	A1	20020703	EP 2000-962682	20000918
EP 1218357	B1	20050406		
R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL	
JP 2003509498	T2	20030311	JP 2001-524974	20000918
EE 200200148	A	20030415	EE 2002-148	20000918
AT 292628	E	20050415	AT 2000-962682	20000918
ZA 2002001831	A	20030605	ZA 2002-1831	20020305
NO 2002001395	A	20020515	NO 2002-1395	20020320

BG 106535	A	20021229	BG 2002-106535	20020320
PRIORITY APPLN. INFO.:			GB 1999-22173	A 19990921
			WO 2000-GB3562	W 20000918
OTHER SOURCE(S):	MARPAT 134:266316			
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB I or a salt, ester, amide or prodrug thereof, a method for the preparation of I and the use of the claimed compds. for inhibiting aurora 2 kinase are claimed. These compds. are useful in the treatment of cancer. In I: X is O, or S, S(O) or S(O)₂ or NR₁₀ where R₁₀ is H or C₁-6 alkyl. R₅ is OR₁₁, NR₁₂R₁₃ or SR₁₁ where R₁₁, R₁₂ and R₁₃ are independently optionally substituted hydrocarbonyl or optionally substituted heterocyclic groups, and R₁₂ and R₁₃ may addnl. form together with the N atom to which they are attached, an optionally substituted aromatic or nonarom. heterocyclic ring which may contain further heteroatoms. R₆ and R₇ are independently H or hydrocarbonyl. R₈ and R₉ are independently H, halo, C₁-4 alkyl, C₁-4 alkoxy, C₁-4 alkoxyethyl, di(C₁-4alkoxy)methyl, C₁-4 alkanoyl, trifluoromethyl, cyano, amino, C₂-5 alkenyl, C₂-5 alkynyl, a Ph group, a benzyl group or a 5-6-membered heterocyclic group with 1-3 heteroatoms, selected independently from O, S and N, which heterocyclic group may be aromatic or nonarom. and may be saturated (linked via a ring C or N atom) or unsatd. (linked via a ring C atom), and which Ph, benzyl or heterocyclic group may bear on one or more ring C atoms up to 5 substituents selected from hydroxy, halo, C₁-3 alkyl, C₁-3 alkoxy, C₁-3 alkanoyloxy, trifluoromethyl, cyano, amino, nitro, C₂-4 alkanoyl, C₁-4 alkanoylamino, C₁-4 alkoxycarbonyl, C₁-4 alkylthio, C₁-4 alkylsulfinyl, C₁-4 alkylsulfonyl, carbamoyl, N-C₁-4alkylcarbamoyl, N,N-di(C₁-4alkyl)carbamoyl, aminosulfonyl, N-C₁-4alkylaminosulfonyl, N,N-di(C₁-4alkyl)aminosulfonyl, C₁-4 alkylsulfonylamino, and a saturated heterocyclic group selected from morpholino, thiomorpholino, pyrrolidinyl, piperazinyl, piperidinyl imidazolidinyl and pyrazolidinyl, which saturated heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halo, C₁-3 alkyl, C₁-3 alkoxy, C₁-3 alkanoyloxy, trifluoromethyl, cyano, amino, nitro and C₁-4alkoxycarbonyl. R₁, R₂, R₃, R₄ are independently halo, cyano, nitro, C₁-3 alkylthio, -N(OH)R₁₄ (R₁₄ is H, or C₁-3 alkyl), or R₁₆X₁- (X₁ represents a direct bond, -O-, -CH₂-, -OC(O)-, -C(O)-, -S-, -SO-, -SO₂-, -NR₁₇C(O)-, -C(O)NR₁₈-, -SO₂NR₁₉-, -NR₂₀SO₂- or -NR₂₁- (R₁₇, R₁₈, R₁₉, R₂₀ and R₂₁ each independently represents H, C₁-3 alkyl or C₁-3alkoxyC₂-3alkyl), and R₁₆ is H, optionally substituted hydrocarbonyl, optionally substituted heterocyclyl or optionally substituted alkoxy). A method for preparing I comprises reacting II where X, R₈ and R₉ are as defined above, R₁', R₂', R₃', R₄' are groups R₁, R₂, R₃, R₄ as defined above resp., or precursors thereof; and R₅' is a leaving group, with HCR₆:CR₇C(O)R₅', where R₆ and R₇ are as defined above, R₅' is a group R₅ as defined above or a precursor group therefore; and thereafter if desired or necessary, converting any precursor groups R₁', R₂', R₃', R₄' or R₅' to groups R₁, R₂, R₃, R₄ or R₅ resp., or changing a group R₅ to a different such group. The compds. of the invention inhibit the serine/threonine kinase activity of the aurora 2 kinase and thus inhibit the cell cycle and cell proliferation. Procedures for assessing these properties are described and test results are given for (E)-4-[4-(2-(3-methylcyclohexylaminocarbonyl)ethenyl)anilino]-6,7-dimethoxyquinazoline.

IC ICM C07D239-94


ICS A61K031-517; A61P035-00
 CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1, 63
 REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 8
 ACCESSION NUMBER: 2001:228864 CAPLUS
 DOCUMENT NUMBER: 134:252355
 TITLE: Preparation of quinazolines as aurora 2 kinase
 inhibitors
 INVENTOR(S): Mortlock, Andrew Austen; Keen, Nicholas
 John
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
 SOURCE: PCT Int. Appl., 101 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001021594	A1	20010329	WO 2000-GB3556	20000918
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2384282	AA	20010329	CA 2000-2384282	20000918
BR 2000014133	A	20020611	BR 2000-14133	20000918
TR 200200749	T2	20020621	TR 2002-200200749	20000918
EP 1218356	A1	20020703	EP 2000-962677	20000918
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003509497	T2	20030311	JP 2001-524973	20000918
EE 200200149	A	20030415	EE 2002-149	20000918
AU 763242	B2	20030717	AU 2000-74325	20000918
ZA 2002001833	A	20030605	ZA 2002-1833	20020305
BG 106491	A	20021229	BG 2002-106491	20020307
NO 2002001401	A	20020521	NO 2002-1401	20020320
PRIORITY APPLN. INFO.:			GB 1999-22152	A 19990921
			GB 1999-22156	A 19990921
			GB 1999-22159	A 19990921
			WO 2000-GB3556	W 20000918
OTHER SOURCE(S):	MARPAT 134:252355			
GI				



I



II

AB Title compds. (I) [wherein X = O, S, SO, SO₂, NH, or NR₈; R₈ = H or alkyl; Ra = (un)substituted 3-quinolinyl or Ph; R₁-R₄ = independently halo, CN, NO₂, alkylsulfanyl, N(OH)R₁₂, or R₁₄X₁; R₁₂ = H or alkyl; X₁ = a direct bond, O, CH₂, OC(O), CO, S, SO, SO₂, or (un)substituted NHCO, CONH, SO₂NH, NHSO₂, or NH; R₁₄ = H or (un)substituted hydrocarbyl, heterocyclyl, or alkoxy; or a salt, ester, or amide thereof] were prepared as aurora 2 kinase inhibitors for the treatment of proliferative diseases, such as cancer. For example, 4-phenoxyaniline•HCl and 4-chloro-6-methoxy-7-(3-morpholinopropoxy)quinazoline were refluxed in i-PrOH to yield II (86%). The latter inhibited the serine/threonine kinase activity of aurora 2 kinase by 50% at a concentration of 0.069 μM. In addition, II gave 50% inhibition of MCF-7 cell proliferation at 2.89 μM and reduced BrdU incorporation into cellular DNA by 50% at 3.68 μM.

IC ICM C07D239-94

ICS C07D401-12; A61P035-00; A61K031-517

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Search history

Truong 10_088854

10/18/2005

=> d his full

(FILE 'HOME' ENTERED AT 12:29:46 ON 18 OCT 2005)

FILE 'REGISTRY' ENTERED AT 12:30:01 ON 18 OCT 2005

D SAV
ACT TRU854STRA/A

L1 STR
L2 5754 SEA SSS FUL L1

L3 STRUCTURE UPLOADED
L4 50 SEA SUB=L2 SSS SAM L3
D SCA

FILE 'STNGUIDE' ENTERED AT 12:31:59 ON 18 OCT 2005

L5 FILE 'REGISTRY' ENTERED AT 13:18:48 ON 18 OCT 2005
STRUCTURE UPLOADED
L6 50 SEA SUB=L2 SSS SAM L5
D SCA

FILE 'STNGUIDE' ENTERED AT 13:20:02 ON 18 OCT 2005

FILE 'STNGUIDE' ENTERED AT 13:23:09 ON 18 OCT 2005

L7 FILE 'CAPLUS' ENTERED AT 13:25:02 ON 18 OCT 2005
16 SEA ABB=ON PLU=ON L6

L8 FILE 'REGISTRY' ENTERED AT 13:25:49 ON 18 OCT 2005
3987 SEA SUB=L2 SSS FUL L5
SAVE L8 TRU854STRG/A

FILE 'CAPLUS' ENTERED AT 13:26:43 ON 18 OCT 2005

FILE 'STNGUIDE' ENTERED AT 13:27:12 ON 18 OCT 2005

FILE 'REGISTRY' ENTERED AT 13:27:35 ON 18 OCT 2005

FILE 'STNGUIDE' ENTERED AT 13:28:21 ON 18 OCT 2005

L9 FILE 'REGISTRY' ENTERED AT 14:23:59 ON 18 OCT 2005
STRUCTURE UPLOADED
L10 0 SEA SUB=L8 SSS SAM L9

FILE 'STNGUIDE' ENTERED AT 14:25:15 ON 18 OCT 2005

L11 FILE 'REGISTRY' ENTERED AT 14:27:20 ON 18 OCT 2005
STRUCTURE UPLOADED
L12 26 SEA SUB=L8 SSS SAM L11
D SCA

FILE 'STNGUIDE' ENTERED AT 14:29:12 ON 18 OCT 2005

L13 FILE 'CAPLUS' ENTERED AT 14:33:19 ON 18 OCT 2005
26 SEA ABB=ON PLU=ON L12

L14 FILE 'REGISTRY' ENTERED AT 14:34:10 ON 18 OCT 2005
89 SEA SUB=L8 SSS FUL L9

This Page Blank (uspto)

SAVE L14 TRU854STRH/A

FILE 'CAPLUS' ENTERED AT 14:35:17 ON 18 OCT 2005

L15 8 SEA ABB=ON PLU=ON L14
L16 296 SEA ABB=ON PLU=ON KEEN N?/AU
L17 66 SEA ABB=ON PLU=ON MORTLOCK A?/AU
L18 8 SEA ABB=ON PLU=ON L16 AND L17
L19 7 SEA ABB=ON PLU=ON L15 NOT L18
L20 0 SEA ABB=ON PLU=ON L19 AND L16
L21 0 SEA ABB=ON PLU=ON L19 AND L17

FILE 'REGISTRY' ENTERED AT 14:42:46 ON 18 OCT 2005

L22 ANALYZE PLU=ON L14 1- LC : 5 TERMS
D

FILE 'USPATFULL, USPAT2, TOXCENTER' ENTERED AT 14:45:14 ON 18 OCT 2005

L23 14 SEA ABB=ON PLU=ON L14

FILE 'REGISTRY' ENTERED AT 14:45:34 ON 18 OCT 2005

FILE 'CAPLUS' ENTERED AT 14:45:37 ON 18 OCT 2005
D STAT QUE L15

FILE 'USPATFULL, USPAT2, TOXCENTER' ENTERED AT 14:48:22 ON 18 OCT 2005
D STAT QUE NOS L23

FILE 'CAPLUS, USPATFULL, USPAT2, TOXCENTER' ENTERED AT 14:50:13 ON 18 OCT 2005

L24 15 DUP REM L15 L23 (7 DUPLICATES REMOVED)
ANSWERS '1-8' FROM FILE CAPLUS
ANSWERS '9-15' FROM FILE USPATFULL
D IBIB ABS HITSTR L24 1-15

FILE 'STNGUIDE' ENTERED AT 14:52:34 ON 18 OCT 2005

FILE 'USPATFULL, USPAT2, TOXCENTER' ENTERED AT 14:54:02 ON 18 OCT 2005

L25 60 SEA ABB=ON PLU=ON KEEN N?/AU
L26 25 SEA ABB=ON PLU=ON MORTLOCK A?/AU
L27 8 SEA ABB=ON PLU=ON L25 AND L26

FILE 'CAPLUS' ENTERED AT 14:54:59 ON 18 OCT 2005
D QUE L18

FILE 'USPATFULL, USPAT2, TOXCENTER' ENTERED AT 14:55:26 ON 18 OCT 2005
D QUE L27

FILE 'CAPLUS, TOXCENTER' ENTERED AT 14:55:50 ON 18 OCT 2005

L28 8 DUP REM L18 L27 (8 DUPLICATES REMOVED)
ANSWERS '1-8' FROM FILE CAPLUS
D IBIB ABS HITIND L28 1-8

FILE 'STNGUIDE' ENTERED AT 14:57:21 ON 18 OCT 2005

FILE HOME

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

This Page Blank (uspto)

STRUCTURE FILE UPDATES: 17 OCT 2005 HIGHEST RN 865410-76-0
DICTIONARY FILE UPDATES: 17 OCT 2005 HIGHEST RN 865410-76-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

FILE STNGUIDE
FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Oct 14, 2005 (20051014/UP).

FILE CAPLUS

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 18 Oct 2005 VOL 143 ISS 17
FILE LAST UPDATED: 17 Oct 2005 (20051017/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

FILE USPATFULL
FILE COVERS 1971 TO PATENT PUBLICATION DATE: 18 Oct 2005 (20051018/PD)
FILE LAST UPDATED: 18 Oct 2005 (20051018/ED)
HIGHEST GRANTED PATENT NUMBER: US6957446
HIGHEST APPLICATION PUBLICATION NUMBER: US2005229280

This Page Blank (uspto)

CA INDEXING IS CURRENT THROUGH 18 Oct 2005 (20051018/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 18 Oct 2005 (20051018/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2005
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2005

```
>>> USPAT2 is now available.  USPATFULL contains full text of the    <<<
>>> original, i.e., the earliest published granted patents or      <<<
>>> applications.  USPAT2 contains full text of the latest US      <<<
>>> publications, starting in 2001, for the inventions covered in   <<<
>>> USPATFULL.  A USPATFULL record contains not only the original  <<<
>>> published document but also a list of any subsequent           <<<
>>> publications.  The publication number, patent kind code, and   <<<
>>> publication date for all the US publications for an invention  <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc.                                                       <<<

>>> USPATFULL and USPAT2 can be accessed and searched together    <<<
>>> through the new cluster USPATALL.  Type FILE USPATALL to      <<<
>>> enter this cluster.                                           <<<
>>>                                                                <<<
>>> Use USPATALL when searching terms such as patent assignees,    <<<
>>> classifications, or claims, that may potentially change from  <<<
>>> the earliest to the latest publication.                        <<<
```

This file contains CAS Registry Numbers for easy and accurate
substance identification.

FILE USPAT2

FILE COVERS 2001 TO PUBLICATION DATE: 18 Oct 2005 (20051018/PD)
FILE LAST UPDATED: 18 Oct 2005 (20051018/ED)
HIGHEST GRANTED PATENT NUMBER: US2004187682
HIGHEST APPLICATION PUBLICATION NUMBER: US2005229256
CA INDEXING IS CURRENT THROUGH 18 Oct 2005 (20051018/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 18 Oct 2005 (20051018/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2005
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2005

USPAT2 is a companion file to USPATFULL. USPAT2 contains full text
of the latest US publications, starting in 2001, for the inventions
covered in USPATFULL. USPATFULL contains full text of the original
published US patents from 1971 to date and the original applications
from 2001. In addition, a USPATFULL record for an invention contains
a complete list of publications that may be searched in standard
search fields, e.g., /PN, /PK, etc.

USPATFULL and USPAT2 can be accessed and searched together through
the new cluster USPATALL. Type FILE USPATALL to enter this cluster.

Use USPATALL when searching terms such as patent assignees,
classifications, or claims, that may potentially change from the
earliest to the latest publication.

FILE TOXCENTER

FILE COVERS 1907 TO 18 Oct 2005 (20051018/ED)

This file contains CAS Registry Numbers for easy and accurate substance

This Page Blank (uspto)

identification.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TOXCENTER has been enhanced with new files segments and search fields.
See HELP CONTENT for more information.

TOXCENTER thesauri in the /CN, /CT, and /MN fields incorporate the
MeSH 2005 vocabulary. See <http://www.nlm.nih.gov/mesh/> and
http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html for a
description of changes.

This Page Blank (uspto)